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Abstract 
 
There are more than 80 pharmaceuticals and pharmaceutical metabolites detected in the 
aquatic environment. Regarding negative impacts of these compounds, the main concern lays 
in sensitive aquatic environment and long-term effects regarding human health and the 
environment. Although we have procedures to assess the risk that pharmaceutical residues 
represent to the environment, these procedures include various assumptions and data gaps. 
Therefore current knowledge is not enough to say how serious the threat is that we are dealing 
with. 
Many concerned governments and organisations apply the precautionary principle (PP) 
regarding the potential risks that pharmaceuticals in the aquatic environment present. This 
means that while there is no full proof about such risks, risk management alternatives are 
nevertheless developed and assessed. In this thesis preventative alternatives and treatment 
alternatives of risk management are discussed. Preventative alternatives include source control 
and source separation as well as increasing awareness. Treatment alternatives include 
wastewater treatment both in centralised systems and decentralised systems. 
Current knowledge about how effective decentralised systems are in removing 
pharmaceuticals is not sufficient. To be able to assess the role that decentralised wastewater 
systems can have in risk management, pharmaceutical removal effectiveness of a bench scale 
recirculating biofilter (RBF) was observed in laboratory experiments. The objective was to test 
if a nitrifying biofilter was able to remove four selected pharmaceuticals (ibuprofen, 
gemfibrozil, naproxen and diclofenac) from pre-treated wastewater. According to the 
laboratory results, ibuprofen, gemfibrozil and naproxen were removed more than 90 percent 
and diclofenac was removed with approximately 70 percent efficiency. These results show that 
there is potential in decentralised systems regarding pharmaceutical removal. However more 
research is needed.  
Local conditions regarding pharmaceutical use patterns, water consumption, and treatment 
technology have an effect on determining the most efficient way to manage this 
environmental risk. Therefore efficient risk management includes both preventative and 
treatment approaches.  
 
 
 
  
Executive summary 
There is scientific evidence that there are traces of pharmaceuticals in our groundwater, 
drinking water, watercourses and wastewater. Wastewater treatment plants are the main route 
for human pharmaceuticals to the environment. So far it is known that the present 
concentrations of pharmaceutical residues do not represent an acute threat to human health 
but there is a reason to believe that other organisms in the aquatic environment suffer from 
this pollution. There are many uncertainties regarding the environmental impact of 
pharmaceuticals and therefore, some governments and organisations have adapted the 
precautionary principle as a guiding approach when dealing with this issue. Even though there 
is no full scientific proof about the level of the risk, they are looking for ways to reduce and 
prevent these pollutants reaching our watercourses. 
This thesis looks into different current possibilities regarding risk management of 
pharmaceutical residues in wastewater. For this thesis two research questions were composed: 
1) How can we manage environmental risks regarding pharmaceutical residues in 
wastewater? 
• What role can decentralised wastewater treatment have as a risk 
management alternative? 
2) How effective is nitrifying Recirculating Biofilter (RBF) for reducing four selected 
pharmaceuticals from wastewater? 
Risk management alternatives can be divided into prevention measures and treatment 
measures. In this study, preventative measures have been discussed based on a literature 
review and include for example source control, source separation and raising awareness of 
stakeholders about the environmental effects of pharmaceuticals.  
Even if we would implement all reasonable preventative measures, pharmaceuticals that are 
consumed usually are excreted and so disposed of with wastewater. Therefore in addition to 
the preventative approach, treatment possibilities have been studied. According to literature, 
conventional centralised wastewater treatment plants can remove or reduce the amount of 
certain pharmaceuticals. The chemical structure of pharmaceuticals and certain treatment 
parameters affect how effective the removal is.  For example, in this study, sludge retention 
time (SRT) and nitrification have been discussed and it seems that long SRT and a good 
nutrient removal increases degradation chances of certain pharmaceuticals. 
Despite the potential of centralised solutions, there is an inevitable fact that a considerable 
share of the population is not, and cannot, be connected to centralised systems. In these 
situations wastewater can be treated onsite in decentralised wastewater systems.  Decentralised 
systems have several benefits when compared to centralised systems including for example 
reduced investments regarding drainage, possibility to recycle nutrients and water reuse, 
flexibility regarding population growth and in the case of operational failure, environmental 
problems are usually smaller when compared to centralised systems. When well maintained, 
treatment results can reach very high standards regarding for example BOD and nutrients 
removal. However there was not information available about how decentralised systems can 
treat pharmaceuticals. 
To be able to evaluate the role that decentralised wastewater treatment systems can have 
regarding risk management and pharmaceutical residues in the aquatic environment, 
  
laboratory experiments were implemented. Testing was done with a bench scale recirculating 
biofilter (RBF). Regarding conventional centralised wastewater treatment systems (WWTS), it 
seems that if the treatment process includes nitrification (conversion of ammonia to nitrate) 
the process can also remove certain pharmaceuticals. Therefore during the experiments both 
ammonia removal and pharmaceutical removal were observed by analysing concentrations in 
system influent and system effluent.  
Based on the laboratory analyses RBF bench scale system was able to remove both ammonia 
and four selected pharmaceuticals. According to the laboratory analyses the average removal 
of gemfibrozil, naproxen and ibuprofen was more than 90 percent and diclofenac was 
removed by average little more than 70 percent. 
It is clear that based on these experiments, it cannot be assessed if the removal efficiency is 
similar regarding field systems and more research is needed to determine this. Results do 
however indicate that it might be possible to remove pharmaceuticals from wastewater with 
field RBF and in addition removal could be possible also with other decentralised systems. 
Today there are no requirements for wastewater treatment regarding pharmaceutical residues 
but this might change in the future when we have a more complete picture about the impact 
of these substances. However it should be noted that wastewater treatment currently, but also 
most probably in the future is focused on removing organic matter and nutrients and it would 
be extremely expensive to design and construct treatment systems that target certain micro 
pollutants. Therefore it is important to know the capacity of current treatment systems 
regarding pharmaceutical removal. Acknowledging the current capacity it is possible to target 
for example preventative measures more efficiently. This means that when we know what we 
can treat we can target our preventative measures to those pollutants that we cannot treat. 
If field studies will show that decentralised systems can have a similar ability to remove 
pharmaceuticals in wastewater than centralised systems, it can mean for example that 
regarding the treatment of these compounds, it is not necessary to prefer centralised 
wastewater systems. This is important for communities with low investment abilities, with 
special needs regarding water reuse and requirements for system flexibility.  
It seems that both in the European Union area and in North America research currently is 
focused to fate research, developing analytical methods and risk assessment measures as well 
as to studying effects of different pharmaceutical residues to the environment. This includes 
the development of different risk management measures. When research covers all levels 
including the risk assessment process and risk management measures, the results benefit the 
whole research sector. For example when we know that naproxen is effectively removed from 
wastewater using conventional treatment methods regarding both centralised and 
decentralised systems, it might not then be a main priority to study how this substance affects 
aquatic organisms. When we know that diclofenac is highly persistent regarding wastewater 
treatment it is possible to consider for example preventative alternatives to deal with this 
specific pharmaceutical. When we learn more about the effects of different pharmaceuticals, 
their fate in the environment and possibilities to prevent or treat this pollution, we can select 
the most efficient risk management measures. This means that in the future we will have 
integrated solutions for risk management including both preventative and treatment 
management approaches. 
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1 Introduction 
 
1.1 Background 
Clean water is essential for living organisms and globally it is a scarce resource. Only three   
percent of earth’s total water volume is fresh water and more than half of this is tied to 
glaciers and icecaps (Gleick, 1996). Currently approximately one of six people worldwide do 
not have regular access to a safe and affordable drinking water source (Joint Monitoring 
Programme for Water and sanitation (JMP), 2004). There are various reasons for this, for 
example water resources can be exploited more than fresh water is generated and because of 
this communities need to start using lower quality water sources. Problems can be also 
economic where people cannot afford safe water and are forced to use unsafe sources. 
Making the problem more severe is the fact that these limited amounts of more accessible 
fresh water resources can be subject to pollution.  
All human activities cause pollution which partly ends up in ground and surface waters. 
According to Miller (2005) “water pollution is related to air pollution, land use, practices, climate 
change, energy use, solid and hazardous waste, and number of people, farms, and industries producing sewage 
and other waste.” Water pollution is considered to be any change (biological, chemical or 
physical) in the water quality that is harmful for living organisms. It should be noted here 
that harmfulness affects both humans and other forms of life. Water pollution has diverse 
effects and it can cause for example different health problems like diarrhoea and 
environmental changes like eutrophication and alteration of food chains. During the last 
decade new concerns about water pollution have developed. 
Developments in analytical methods have made it possible to measure lower and lower 
concentrations of pollutants in water. One new group of pollutants that is now possible to 
track is Pharmaceuticals and Personal Care Products (PPCPs). Low concentrations of these 
have been found in Europe and in North America in drinking water sources, in rivers, 
groundwater and in wastewater effluents. Even though concentrations have been low, and 
might not have an acute effect to human health when quantities remain at the present level, 
we do not know the long term effects these substances may have. Also because unlike other 
pollutants, pharmaceuticals are designed to have a reaction in human body, we should ask: is 
a reaction possible in other organisms. Aquatic environments are sensitive. It is a possibility 
that bacteria exposed to pharmaceuticals may become resistant to disinfection and the 
increasing use of pharmaceuticals and personal care products have raised concern about the 
fate and effects of these compounds. Therefore we can state that these compounds 
represent a possible environmental risk and implementing the precautionary principle (PP) 
can be justified.   
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According to the precautionary principle, even when there is no full scientific proof of the 
level of the risk that these substances represent; the lack of scientific evidence should not 
forbid us to act and try to prevent and reduce this risk, when there is a sufficient reason to 
believe that these substances indeed are harmful to the environment (Rio Declaration, 1992). 
Measures that we can take to prevent or reduce the risks are called risk management 
measures. There are many different approaches that can be used to manage risk and these 
can include preventative and treatment alternatives. Preventative approaches can include for 
example preventing pharmaceuticals and personal care products from reaching water 
systems by using source control and waste separation. In addition we can also use treatment 
as a risk management alternative and in this case wastewater treatment would be the first 
option to look into since one of the main routes of entry for pharmaceuticals to the 
environment goes through wastewater treatment plants. Very often wastewater treatment is 
performed in conventional centralised systems, which means that a large facility collects the 
community wastewater through sewage collection system and wastewater is then treated 
using a series of processes. However it is important to notice that centralised wastewater 
treatment service is not available for everybody. There is a large population in countries like 
Sweden, Finland, the United States and Canada as well as in many other countries that are 
living in rural areas and are not connected to centralised sewerage. In such instances onsite 
wastewater treatment can be used to replace the common centralised system. The use of 
these decentralised systems has been considered to be an environmentally preferred 
approach to the wastewater treatment since water is treated near the place it has been 
generated and so there is the possibility to save resources.  
It is known that conventional centralised wastewater treatment plants can reduce the amount 
of some pharmaceuticals in wastewater, but at the moment there are no studies available 
demonstrating the effectiveness of decentralised systems in dealing with such substances. 
Therefore it is important to assess the role of decentralised wastewater systems to have a 
more complete picture about choices we have regarding risk management.  
There are various different decentralised wastewater treatment applications that use several 
different treatment technologies. Recirculating Biofilter (RBF) is one of these. It is 
scientifically researched, easy to use and highly effective regarding BOD and pharmaceutical 
removal (Farzana, 2008; Hu, 2006). Due to such characteristics RBF forms a good candidate 
to investigate the pharmaceutical removal potentials of decentralised wastewater treatment 
plant units. 
This thesis is targeted for professionals in municipalities that are making decisions about 
wastewater treatment systems as well as for those who develop and produce decentralised 
wastewater treatment systems. It also presents information for policy developers as well as 
other parties interested about pharmaceuticals in the aquatic environment. This thesis has 
been written for International Institute for Industrial Environmental Economics (IIIEE) in 
Lund University, Sweden for the Master of Science program in Environmental Management 
and Policy. 
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1.2 Research objectives 
The goal of this thesis is to contribute to the general understanding regarding risk 
management alternatives for pharmaceuticals in the aquatic environment. 
To reach this objective, the research concentrates on the following questions: 
 
1) How can we manage environmental risks regarding pharmaceutical residues in 
wastewater? 
• What role can decentralised wastewater treatment have as a risk 
management alternative? 
2) How effective is the nitrifying Recirculating Biofilter (RBF) for reducing selected 
pharmaceutical substances from wastewater? 
 
1.3 Methodology 
1.3.1 Literature review 
In the first stage of the research a desktop study is performed in order to achieve a general 
understanding about the relationship regarding pharmaceutical residues and the 
environment. Information about environmental risk assessment regarding pharmaceuticals, 
the policy directions in the European Union (EU) and North America about 
pharmaceuticals and the environment, and descriptions about wastewater treatment 
technologies were gathered. Studies about occurrence and fate of different pharmaceuticals 
and potential risks that pharmaceuticals represent were searched. Literature review was 
carried out focusing to studies that were done in the European Union area and in North 
America. 
An assessment was completed on the current state of policy and perceived risk level in the 
European Union and North American regulatory agencies. Also research topics supported 
by government were screened and compared. This information was gathered using publicly 
available internet sources and published sources from Environment Canada, the United 
States Environmental Protection Agency (USEPA) and the European Union. 
1.3.2 Assessment of centralised and decentralised wastewater 
treatment 
Wastewater treatment technologies used both in centralised and decentralised systems were 
studied, and the benefits and shortcomings of each system were assessed. Descriptions of 
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different treatment technologies were extracted mainly from engineering study books.  
Legislation concerning wastewater treatment requirements in general in the EU and Canada 
were examined, and in addition requirements for decentralised systems were studied using 
Finish and Swedish sources. Legislation issues as well as regulations and requirements 
concerning pharmaceuticals and wastewater were obtained from environmental 
administrations with publicly available internet pages. Scientific articles about conventional 
wastewater treatment plants’ ability to reduce pharmaceuticals in wastewater were reviewed 
to get an understanding about the potential and limitations of these technologies regarding 
certain pharmaceuticals. Scientific articles were searched from the European Union area, 
Canada and the United States. 
The objective for the second step was to study if it is possible to reduce pharmaceuticals 
from wastewater using RBF. Experiments were done with a bench scale RBF in a laboratory 
conditions. First the bench scale system was observed regarding nitrification (ammonia 
removal) since it was assumed that this has an effect on pharmaceutical removal. This 
assumption was based on research done with centralised systems that has shown that 
systems that are nitrifying are also able to reduce the amount of certain pharmaceuticals 
(Servos & al., 2005; Assessment of Technologies for the Removal of Pharmaceuticals and 
Personal Care Products in Sewage and Drinking Water Facilities to Improve the Indirect 
Potable Water Reuse (POSEIDON), 2004). During the first experimental step the treatment 
system used different filter media to observe its affect to the ammonia removal. Nitrification 
efficiency was studied by analysing ammonia concentration from influent and effluent. 
During the second experimental step four different pharmaceuticals were fed to the biofilter 
system. Then the influent and effluent were analysed regarding both ammonia 
concentrations and pharmaceutical concentrations. A more detailed description about the 
experiments is presented in the Chapter 3. 
The pharmaceutical agents that were selected for this research represent are commonly used 
drugs and have been studied in centralised systems. The results for laboratory analyses were 
compared with the results presented in scientific articles from centralised systems. 
Comparison was done to see if there were differences in the ability to remove 
pharmaceuticals when comparing centralised and decentralised systems. 
Using the results of RBF experiments on the system’s ability to remove ammonia and 
pharmaceuticals from wastewater, a statistical analysis was performed. To evaluate the 
significance of the results a “paired t-test” was used. This statistical analysis was selected 
because the samples that were taken from the system could be paired accordingly as they 
were taken at the same time (samples from the influent and effluent were collected within a 
short time interval). Even though it is not possible to sample exactly the same parcel of 
water in RBF system (i.e., the pairing is not exact), according to Berthouex & Brown (2002) 
“any variation caused by this will be reflected as a component of the random measurement error”. In the 
paired t-test the analysis is done by averaging the difference of each pair of sample results 
and to calculate if the average of these differences is different from zero. Pharmaceutical 
removal efficiency was analysed and the 95 percent confidence- intervals were calculated for 
each tested drug. 
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1.4 Scope 
The focus of this thesis is in human pharmaceutical residues in wastewater. Even though 
there are also other micro pollutants found in wastewater, for example personal care 
products, pharmaceuticals were chosen as a main topic.  This was for two reasons:  firstly, it 
is impossible to prevent all of these substances from ending up in the wastewater even when 
preventative measures are included and secondly, they are targeted to react in a human body 
and there is reason to believe that the reaction is possible also in other organisms. 
Current occurrences of pharmaceutical residues in the aquatic environment is presented 
from the European Union and North American points of view. Policies and the legal 
requirements for wastewater treatment and removing pharmaceuticals from wastewater are 
discussed following Canadian and North European (Sweden and Finland) regulations and 
visions. 
The focus of this thesis is in decentralised wastewater treatment as a risk management 
alternative and examines the application of decentralised RBF system for pharmaceutical 
removal. The ability for decentralised systems to remove pharmaceuticals from wastewater is 
assessed by implementing laboratory experiments with a bench scale RBF. Pharmaceuticals 
that were selected for the experiments were gemfibrozil, naproxen, diclofenac and 
ibuprofen. These pharmaceuticals were selected since they are commonly used, their 
degradability, that is different for each compound, has been studied regarding centralised 
wastewater treatment, and analytical methods for the selection of these pharmaceuticals are 
available. 
1.5 Limitations 
This thesis focuses on domestic sources of pharmaceutical residues even though there are 
different pharmaceuticals used also for veterinary purposes. Veterinary products are 
excluded from this study since the main routes of entry are different than human 
pharmaceutical residues. Also personal care products are not included because they have 
different use patterns and purposes than pharmaceutical agents. 
Risk assessment can be divided into 1) environmental risk assessment and 2) risk assessment 
for human health. In this study only environmental risk assessment is briefly described to 
give the reader an overview about the process. Regarding environmental risk management 
both treatment and preventative measures are included. However the former, not the latter is 
the primary focus. Treatment is discussed both from centralised wastewater treatment 
systems and decentralised wastewater treatment systems point of view, the main focus being 
in decentralised systems. Because of this focus, advanced treatment methods for centralised 
systems (ozonation and membrane technology) are only briefly discussed. Wastewater 
treatment process produces sludge that can contain pharmaceutical residues. However 
sludge treatment has been excluded from this thesis. 
Hannamaria Yliruusi, IIIEE, Lund University 
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Different use patterns of pharmaceuticals and water alongside wastewater treatment 
technologies affect pharmaceutical removal. This might have an effect to the results of this 
thesis 
Experiments done with RBF cannot be used to predict how pharmaceuticals can be 
removed with decentralised systems in general, as other systems may use different removal 
mechanism other than biofilters. Results of this study describe how RBF can decompose 
these chemicals in laboratory conditions.  As such, results can only give indications how 
pharmaceuticals can be removed with field applications. Also it should be noted that the raw 
wastewater used in experiments was gathered from a centralised wastewater treatment plant 
so there might be a difference in characteristics of wastewater that was used for the 
experiments and wastewater that is usually emitted to the decentralised systems. Experiments 
were done by using selected pharmaceuticals so the results should not be applied as a generic 
model for all pharmaceutical agents.  
1.6 Thesis outline 
Chapter 1 Introduction contains background information for this thesis providing 
information about the topic, stating research objectives and discussing the scope and 
limitations of this study.  
In Chapter 2 Pharmaceutical residues in the aquatic environment, the reader will be 
given an overview about how and why pharmaceuticals end up in our watercourses and how 
different characteristics of pharmaceuticals affect their occurrence in the aquatic 
environment. The risk that these substances represent, what is seen by the scientific 
community, and the description of environmental risk assessment for pharmaceuticals is 
discussed. In this chapter the implementation of the precautionary principle regarding 
environmental impact of pharmaceuticals is discussed. Different risk management 
approaches, preventative and treatment measures, are presented and their strengths and 
weaknesses are weighted. This chapter includes introduction to wastewater treatment and 
both centralised and decentralised wastewater treatment systems are assessed. Also design 
parameters and operational characteristics that have an effect to the pharmaceutical removal 
efficiency are explained. 
In the Chapter 3 Case study: Recirculating Biofilter (RBF), the reader will find 
information about RBF treatment application and benefits and weaknesses of this system. 
This chapter includes a description about the laboratory experiments that were implemented 
with a bench scale RBF system. The results of the experiments are presented. This chapter is 
targeted to those who are interested about the details of laboratory experiments. 
In the Chapter 4 Discussion the results of the laboratory experiment are presented and 
compared to other studies. Policy direction and the relationship to the precautionary 
principle are discussed and efficient risk management measures weighed. 
Chapter 5 Conclusions and recommendations provide a summary of this thesis and 
recommendations for future research. 
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2 Pharmaceutical residues in the aquatic environment 
 
Drugs or pharmaceuticals in this study are defined following Gunnarssons & Wennmalms, 
(2006) definition that states that they are products that are designed to diagnose, cure or 
alleviate disease. These products are usually made from active substances, excipients and 
packaging. The active substance is the main element of the product and excipients can be 
designed to give the drug a proper volume, sufficient shelf life or make it for example easier 
to take.  
There are more than 80 different compounds, pharmaceuticals and pharmaceutical 
metabolites, detected in the aquatic environment in the Europe, U.S, Canada and Latin 
America.  Pharmaceuticals like analgesics and anti-inflammatory drugs that are generally used 
as pain killers, antibiotics, antiepilectic drugs, beta-blockers, blood lipid regulators, iodinated 
X-ray media, cytostatic drugs, contraceptives etc. have been detected in sewage, drinking 
water, groundwater and watercourses. Since the human body does not completely 
metabolize pharmaceuticals they are excreted slightly transformed or even unchanged, and 
end up in water systems. Measured concentrations have been low, for example in sewage 
influents and effluent samples have been up to the μg/l –level, so detecting these 
compounds from water has been possible only in the past ten years since developments in 
analytical methods (National Water Research Institute NWRI, 2007; Heberer, 2002). 
The main routes of entry for the pharmaceutical residues to the aquatic environment are 
wastewater and wastes and the biggest points of pollution are wastewater treatment plants. 
Septic fields, landfills that leach to the groundwater and storm water overflow from 
residential sources can also be sources for these chemicals (Backus, 2007). Agriculture may 
contribute to the occurrence of pharmaceuticals in the environment because of the use of 
veterinary drugs and feed additives for livestock. Also manure use as fertilizer can lead to a 
leakage of these compounds to the surface waters (Herberer, 2002).  
Pharmaceuticals represent a versatile group of chemical compounds. In general chemicals 
can be harmful and toxic because of many different mechanisms. For example chemicals can 
bind to molecules such as hormones, DNA and RNA, lipid membranes and proteins. This 
interaction can destroy these molecules or modify their structures potentially leading to 
changes in physiological functions. Pharmaceuticals can bind to transport proteins or 
receptors that are designed for hormones and block or enhance a natural function.  They can 
also block the function of enzymes. Pharmaceuticals however differ from other chemicals in 
a way that they are designed to have an effect in the human body, and they can for example 
be designed to target enzyme and hormone systems of humans. These hormonal systems are 
in all probability also present in lower trophic level organisms, hence pharmaceuticals can 
affect other organisms, such as mammals, fish and lower order species and even plants 
(Breitholtz & Bengtsson, 2006; Gunnarsson & Wennmalm, 2006). 
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Since most pharmaceuticals are designed to be swallowed, the active substance needs to 
survive through the stomach acidic environment and must be resistant. Pharmaceuticals 
contain a wide range of compounds that have very different chemical and physical 
properties. The harmfulness of pharmaceuticals to the environment and/or human health is 
dependent on various properties such as:  degradability (describes how fast substances are 
degraded), volatility (tells how easily a substance is passed into the gas phase and so 
determine how much of a certain substance can be transported to the atmosphere and react 
there), and water solubility (describes how easily a substance can be dissolved in to water). 
According to Tysklind & Fick (2006) pharmaceuticals can be divided in three different 
categories regarding solubility. First those that break down easily, second those that are 
water-soluble and third those that are fat-soluble. Water-soluble substances are found 
naturally in water and they are transported by the water cycle. Fat-soluble substances can be 
found in sediments and soil and they have a tendency to accumulate in food chains. 
Following this categorisation, pharmaceuticals like acetylsalicylic acid that breaks up easily 
can be found only near to the sources when there are large amounts of it released. Some 
lipid-lowering drugs that are water-soluble and stable can pass through the wastewater 
treatment plant and disperse into the receiving water system more or less unchanged. Some 
antibiotics (e.g. fluoroquinolones) are fat-soluble and stable and are absorbed to sludge 
particles in wastewater treatment process and can be released back to the environment when 
sludge is disposed. 
The potential for a pharmaceutical to enter the environment and the level of concentration 
in watercourses is dependent for example on the volumes of that drugs that are used, how 
these pharmaceuticals behave in the human body (meaning if they metabolise well or if they 
are extracted unchanged to the wastewater) and also and how well wastewater treatment 
plant and drinking water facility or natural water systems can eliminate the pharmaceutical 
compound (Metcalfe & al., 2003). Concentration of pharmaceuticals in wastewater varies for 
different pharmaceuticals in different countries. This can be explained with different drug 
use patterns, differences in water consumption and differences in wastewater treatment 
technology (Lishman & al., 2006; Metcalfe & al., 2003). 
Various factors can affect the use patterns and consumption of pharmaceuticals. One is that 
there are demographic differences between countries. The proportion of elderly in the 
population and shares of men and women can have affects upon use patterns and consumed 
volumes. Variation in therapeutic traditions, prescribing habits, availability of 
pharmaceuticals as well as the variation in over-the-counter drugs influences which and how 
much of pharmaceuticals are consumed (Nordic Medico- Statistical Committee 
(NOMESCO), 2004). 
At the moment there seems to be a consensus that present concentrations of 
pharmaceuticals in the environment are not an immediate threat for human health (e.g. 
Christensen, 1998; Schwab & al. 2005; Breitholtz & Bengtsson, 2006). Consumption of 
pharmaceuticals is however, increasing for example in the Nordic Countries (NOMESCO, 
2004). Also in Canada during the past 10 years the number of prescriptions filled has 
increased significantly (Paris & Docteur, 2006). According to Redshaw & al. (2008) there is a 
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potential for accumulation of certain pharmaceuticals. Accumulation can occur for example 
when sewage sludge is used as soil fertilizer or disposed. This raises concern that 
concentration levels in the environment could be higher in the future and that threshold 
limits regarding human health might be passed. 
Since species share similar hormone and enzyme systems, pharmaceuticals that are designed 
to have an effect in these systems in humans can have similar but also totally different effects 
in other species and organisms. Therefore pharmaceutical residues in the aquatic 
environment are considered to be a potential risk to other species. According to Breitholtz & 
Bengtsson (2006), unintended intake of pharmaceuticals by humans is limited usually to 
drinking and cooking water.  On the other hand organisms living in the aquatic environment 
are exposed to these chemicals via their gills during oxygen replenishment. Organisms that 
are small or at young stage, can have very thin wall separating them from the aquatic 
environment and so osmotic transport can become an important route of entry. Some 
organisms live in sediments and/or feed by filtering particles suspended in the water, hence 
they expose themselves to chemicals that are not easily soluble in water and tend to bind to 
these particles. According to Gross-Sorokin, Roast, & Brighty (2006) it seems that estrogen 
emissions could be causing for example increasing number of hermaphrodite fish in English 
rivers. Gagné, (2007) states that “ there are indications that some aquatic species are likely to 
accumulate some drugs and that they are likely to produce harmful effects on fish”.    Cleuvers (2002) 
points out that even though acute effects in the aquatic environment seem unlikely 
“considerable combination effects can occur”. 
2.1 Environmental risk assessment of pharmaceuticals 
Risk assessment is a way to evaluate how big a threat pharmaceutical residues are in the 
environment. Risk is considered by the United States Environmental Protection Agency 
(USEPA, 2008b) considered to be: 
“the chance of harmful effects to human health or to ecological systems resulting 
from exposure to an environmental stressor. A stressor is any physical, 
chemical, or biological entity that can induce an adverse response. Stressors may 
adversely affect specific natural resources or entire ecosystems, including plants 
and animals, as well as the environment with which they interact.“   
According to this definition pharmaceutical residues in the aquatic environment can be seen 
as chemical stressors that can have harmful effects on human health or to the ecological 
system. To be able to estimate if this potential risk is something that must be dealt with, one 
can perform risk assessments. A risk assessment can be determined in various ways. A risk 
analysis can be defined as: 
“an assessment of the probability that adverse effects will occur and of their 
possible extent” (Statens offentliga utredningar (SOU), 1984). 
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Risk analysis is a demanding procedure where quantitative estimates of the probability of 
adverse effects occurring are included. A precise assessment is seldom done, and a more 
common way to assess risks is by risk characterisation, which is: 
 “An estimation of the incidence and severity of the adverse effects likely to 
occur in a human population or environmental compartments (e.g. soil, air or 
water) due to actual or predicted exposure to a substance, and may include a 
“risk estimation”, i.e. the quantification of this likelihood (Technical 
Guidance Document (TGD), 2003).  
One component in risk assessment is the hazard analysis that assesses the properties of 
chemicals that cause effects on the environment (SOU, 1984). 
The USEPA (2008b) divides risk assessment into two main categories 1) Human Health Risk 
Assessment and 2) Ecological Risk Assessment (in this thesis Environmental Risk 
Assessment (ERA)). Risk assessment discussed in this study as a procedure for 
environmental risk assessment. ERA is a combination of different sub-analysis and it is 
usually implemented as step-by-step process (see Figure 2-1) According to TGD (2003) the 
main elements (steps) of a risk assessment are: 
  •        hazard identification; 
  •        dose (concentration) - response (effect) assessment; 
  •        exposure assessment; 
  •        risk characterisation. 
Risk assessment is based on gathered data that can vary within very wide limits concerning 
both data quality and extent. Therefore risk assessment contains varying degrees of 
uncertainty, compensated for by using different application factors. These factors are 
discussed more in detail below (Gunnarsson & Wennmalm, 2006; Lundgren, 2006).  
The objective of the first step, hazard identification, is to identify substances relevant to 
environmental effects and their dose-response relationships. This is done based on the 
information of substances and their inherent chemical and physical properties and 
information about the substance’s ecotoxicological properties (Gunnarsson & Wennmalm, 
2006; Lundgren, 2006).  
During the second step, effect assessment, the Predicted No Effect Concentration 
(PNEC), is determined. PNEC can be calculated for different environmental compartments 
- for example for sewage treatment plants (micro-organisms), inland water (organisms living 
in water and sediment), terrestrial ecosystems and groundwater etc. - separately. PNEC is 
formed using data about the concentration of active substance that does not have effect to 
three defined aquatic organisms. If one organism is more sensitive to the substance than the 
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other the lower concentration is chosen in the evaluation. Here an assessment factor is 
included to compensate various uncertainties of the data (for example that there might be 
more sensitive organisms that has not been tested or that tests are done to show acute 
effects and not chronic exposure) (Gunnarsson & Wennmalm, 2006; Lundgren, 2006). 
During the third step, exposure assessment, Predicted Environmental Concentration 
(PEC) is calculated. When calculating PEC it is possible to estimate the concentration of a 
certain substance in the environment. This can be done for example by calculating the 
quantity of the active substance in the product that is sold, consumed (assumption that 
everything that is sold is also consumed) and excreted and dividing this by the volume of 
used water (dilution of the substance). PEC is also corrected with assessment factor 
(Gunnarsson & Wennmalm, 2006).  
The last step in risk assessment is to combine earlier steps by comparing PEC and PNEC. 
If PEC is greater that PNEC active substance can have adverse effects in the aquatic 
environment. However if the value of PEC is smaller from these two the active substance 
should in theory, not have an adverse effect on the aquatic environment. It should be noted 
that this type of an assessment can give only an approximate idea of the risk of 
environmental effects and this method includes many approximations that can over- and 
underestimate the risk (Gunnarsson & Wennmalm, 2006).   
 
Figure 2-1. Risk assessment process for pharmaceuticals.(Source: Lundgren, 2006:108) 
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There is a need to have standardised methods for the implementation of different steps 
within environmental risk assessments. This has been an objective for the European Union 
financed project Environmental Risk Assessment of Pharmaceuticals (ERAPharm). This 
project follows risk assessment steps and it is divided in three different stages: 1) fate and 
exposure assessment; 2) effect assessment; and 3) environmental risk assessment. Fate and 
exposure studies are looking into environmental variables and how they affect the fate of 
pharmaceuticals in water. Also models for predicting the concentrations of pharmaceuticals 
in water and other environments are developed. During the effect assessment different tests 
are evaluated based on how helpful for risk assessment they can be. This stage also includes 
studies about effects that certain pharmaceuticals have in different organisms. The objective 
of environmental risk assessment stages are to evaluate action limits and trigger values of 
environmental risk assessment procedures. The overall goal is to gain a more complete 
picture about risk assessment of pharmaceuticals and to develop improved guidance on the 
environmental risk assessment of pharmaceuticals (ERAPharm, 2008). Similar studies are 
currently implemented in North America (USEPA 2008a; NWRI, 2007).  
According to Lundgren (2006), there are three possible conclusions based on risk 
assessment: 1) more  information and testing is needed; 2) there is no need for further 
information gathering and testing and there is no need for risk reduction measures; and 3) 
there is a need for limiting (managing) the risks (Lundgren, 2006).  
However, as we understand the ERA procedure presented earlier, risk assessment currently 
contains many uncertainties. Data gaps and various assumptions need to be included to the 
assessment process for example in a form of assessment factors. It is important to consider 
the procedure, how it is implemented currently, the missing data, and these subsequent 
effects on the interpretation of the results of these assessments.  
One way to acknowledge data gaps and uncertainty included to the ERA process is to apply 
the precautionary principle (PP). The PP was introduced in 1992 in the Rio Declaration in 
Principle 15 in a following way:  
“In order to protect the environment, the precautionary approach shall be 
widely applied by States according to their capabilities. Where there are threats 
of serious or irreversible damage, lack of full scientific certainty shall not be 
used as a reason for postponing cost-effective measures to prevent environmental 
degradation.” (The Rio Declaration, 1992)  
According to Grandjean (2005) there are two key elements regarding PP. First it justifies our 
acts (e.g. policy guidance) when we are uncertain of the risks from environmental exposures 
and when there is “limited but plausible and credible” scientific evidence of “likely and substantial” 
harm. Second, the burden of proof should be shifted “from demonstrating the presence of risk 
toward demonstrating the absence of risk.” (Enick & Moore,2007; Grandjean, 2005) 
Enick & Moore (2007) state that regarding pharmaceuticals and the environment, we should 
not forget the context of the ERA process which is “as critical to the output of the risk assessment 
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as is the numerical data that is used for risk assessment derivation”. They continue by stating that 
scientific objectivity is necessary but not sufficient to direct policy development and that it 
should be noted that “The recognition that ERA [Environmental Risk Assessment] is a scientific 
process dependent on its current social context has the potential to increase the accuracy and transparency of 
the risk evaluation system.” They point out that when we have acknowledged inherent 
uncertainty the ERA precautionary principle needs to be applied regarding policy 
development. This raises a question: in which stage should we integrate the PP into risk 
assessment process? Enick & Moore (2007) state that it should be integrated to the risk 
assessment process already in the early stage as in if the PP is included when risk reduction 
measures are considered, it is already too late. They support this statement by stating that the 
outcomes of risk assessment are often irreversible, for example, “if a substance is initially 
assessed as being non-toxic, but further use/research proves it to be toxic ... , some of the effects may be 
mitigated but the damage to the affected individuals cannot easily be eliminated.”  
The aquatic environment in general is a sensitive ecosystem that includes various different 
species that have developed for example complicated mutual dependencies and 
specialisations (Breitholtz & Bengtsson, 2006). We know that there are indications that 
pharmaceuticals might be harmful for some aquatic organisms already when concentrations 
are at the current level (Gagné, 2007; Gross-Sorokin, Roast, & Brighty, 2006). In addition 
the consumption of pharmaceuticals is increasing (NOMESCO, 2004) and we know that 
some of these pollutants can potentially accumulate (Redshaw & al., 2008). We have also 
acknowledged that we have data gaps and therefore, risk assessments include various 
assumptions. Considering this one can interpret that conditions to apply the PP are fulfilled. 
Even though there is no full scientific proof of the level of the risk, various organisations 
and governments have adapted the precautionary principle and they are already taking steps 
to assess and develop risk management measures (NWRI, 2007; Assessment of Technologies 
for the Removal of Pharmaceuticals and Personal Care Products in Sewage and Drinking 
Water Facilities to Improve the Indirect Potable Water Reuse (POSEIDON), 2004).   
2.2 Preventative risk management approaches 
We have wide selection of measures that we can use to prevent or reduce environmental 
risks. In this study risk management approaches are divided to preventative alternatives and 
treatment alternatives. 
The pollution prevention approach has been successful considering many other pollutants. 
According to USEPA (2008c); 
“Pollution prevention (P2) is reducing or eliminating waste at the source by 
modifying production processes, promoting the use of non-toxic or less-toxic 
substances, implementing conservation techniques, and re-using materials rather 
than putting them into the waste stream”.  
Regarding pharmaceuticals it is possible for the pharmaceutical industry to modify 
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manufacturing processes so that less residues are produced – during production or in the use 
- or to select less environmentally harmful substances for the pharmaceuticals. However, 
domestic use is an important issue in this matter and solutions that are good for the industry 
are not valid. Therefore, it might be beneficial to understand pollution prevention as any act 
that is taken to reduce waste before its disposal and treatment. In this study two preventative 
approaches are discussed 1) source control and 2) waste separation.  
2.2.1 Source control 
Source control and life cycle management approaches are considered to be beneficial ways to 
reduce pharmaceuticals in the environment. Implementation would require raising 
awareness of consumers about the effects that pharmaceuticals have in the environment 
and secondly, educating public how to prevent negative impacts when using and disposing 
of pharmaceuticals. Collaboration by all stakeholders, government, pharmaceutical industry, 
pharmacist associations, the media and the education system is considered to be important 
(NWRI, 2007). There are different ways to raise awareness and activate stakeholders and one 
interesting suggestion would be to use ecolabelling. Ecolabels are used already globally and 
for example ecolabel Swan that is used in European Nordic Countries have schemes to 
assess product groups within personal care products (Joutsenmerkki, 2008). Ecolabelling 
provides information for consumers about ecological characteristics of a product so that 
consumers can make decisions about what products to buy or not to buy. The mechanism to 
include pharmaceuticals to existing ecolabel schemes is not however known, and currently 
there are no official international standards about how to classify pharmaceuticals regarding 
their environmental impacts.  
One option could be to use classification models for pharmaceuticals that are developed 
in Sweden. There are two models. “The Stockholm model” was developed by the Stockholm 
County Council, Apoteket AB, Swedish Chemicals Inspectorate and other ecototoxicology 
experts. It aims to provide environmental information about pharmaceuticals for patients 
and prescribers. The objective is to encourage pharmaceutical companies to consider 
environmental issues when developing new pharmaceuticals and reduce the impact that 
these products have. According to this model pharmaceuticals are assessed for their 
biodegradability, potential bioaccumulability and toxicity to aquatic organisms. 
Pharmaceuticals are assigned a value based on these characteristics, which describe the 
harmfulness to the environment.  The higher the value, the more harmful is the 
pharmaceutical. The second model, “the Swedish model”, is an initiative of the Swedish 
Association of the Pharmaceutical Industry (LIF), the Swedish Medical Products Agency, 
Apoteket AB, the Swedish Association of Local Authorities and Regions and Stockholm 
County Council. While the first model is based on assessment of inherent environmental 
hazards the second model is based on a combination of hazard and risk assessment. The 
results of this combined assessment are presented to three different target groups: patients, 
prescribers and specialists. The content of the information for these groups varies so that it 
is most specific regarding specialists (Gunnarsson & Wennmalm, 2006).  
Even though it is important to have information available about environmental impacts of 
pharmaceuticals, it does not necessarily mean that consumers are making environmentally 
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sound decisions. Keeping in mind that pharmaceuticals are meant to heal or prevent 
illnesses, it is not likely that medication would not be taken because it is or can be harmful to 
the environment. On the other hand, it might be that if there are two alternative 
pharmaceuticals that have a same effect, it is possible for customers to choose the one with 
less environmental impact.  
In addition to the schemes that are targeted to give information for consumers it is possible 
to control the amount of pharmaceuticals ending to watercourses by reducing medical 
consumption. Even though medical treatment obviously should not be reduced just 
because of the environmental impact, we can include to our preventative risk management 
alternatives measures that prevent illnesses and so minimise the need to use pharmaceuticals. 
These measures are versatile selection of policies and approaches from general health 
education to tax policies. Also, it would be beneficial not to medicate “just in case”.  Since 
the use of pharmaceuticals is increasing it might be that we sometimes take medication 
unnecessarily. Reducing unnecessary pharmaceuticals consumption can also have benefits 
regarding public health and public costs.  
Regarding attempts to reduce pharmaceutical consumption it should be noted that different 
countries have different mechanism to support pharmaceutical use. For example 
governments have different schemes to subsidise these products for consumers. Also it 
might be that a doctor’s salary is dependent of the amount of prescriptions he or she gives. 
Different countries can have very different health care cultures and there might be 
mechanisms that prevent actions to reduce the use of pharmaceuticals.  It is important to be 
aware of these kinds of structures when designing risk management alternatives. 
In addition to information one reasonable approach could be product take-back programs 
for pharmaceutical residues. For example in Canada campaigns for a consumer to return 
residual drugs to the pharmacist at no extra charge have been implemented. However 
according to NWRI (2007) in Canada these take-back programs need to be further studied 
to analyse their cost-effectiveness. In Finland residual drugs are classified as hazardous waste 
and consumers are allowed and encouraged to return them to any pharmacy without an extra 
fee. Medical waste is gathered from pharmacists and it is then treated in a special waste 
treatment plant. In Sweden a similar system is used and there it has been estimated that 65 
percent of residual drugs are returned to the pharmacy (Castensson & Gunnarsson, 2006). 
Take-back programs do not only benefit the environment but also they prevent 
pharmaceuticals from getting into the hands of people that should not be using them since 
unused pharmaceuticals are not disposed with conventional domestic waste.  
One interesting scheme would be to implement extended producer responsibility and 
involve producers to participate in residual pharmaceutical disposal. Take-back programs 
financed by manufactures could be a good way to involve pharmaceutical industry. Usually 
customers need to get pharmaceuticals from special shops (pharmacist) and this makes 
collection for this kind of a waste quite simple as the Swedish and Finish examples show. 
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2.2.2 Source separation 
Source control is however not the only way to deal with pharmaceuticals ending up in the 
aquatic environment and source separation is worth consideration. Source separation means 
that pharmaceutical waste streams are separated from other wastes and then treated. 
This could mean that we collect and treat for example wastewaters that we know are more 
concentrated before discharging it to the sewage system. This could be implemented in 
various ways and for example industrial, hospital and nursing home wastewater could be 
treated onsite before discharging it to the common sewage. Regarding the definition above 
we could include take-back programs to this category. 
Since high amounts of pharmaceuticals are excreted via urine, it is possible to use urine 
separation to separate more concentrated waste stream from less concentrated stream. 
Separated urine is then possible to treat in terms of both pharmaceuticals and nutrients. 
Since urine constitutes less than 1 percent of the wastewater volume but contains most of 
the nutrients that end up in wastewater, this approach would also give benefit in nutrient 
removal and it can offer an option for nutrient recycling. However this approach would 
require adjustment in toilet seats and possibly in drainage and so would need investments 
from home owners as well as operators of the sewage collection systems. Also for example 
Larsen & al., (2004) states that removal mechanisms in source separated urine are not yet 
fully developed and technology lags behind when it is compared to research in conventional 
wastewater treatment plants.  
The preventative approach has been successful both in industry and households concerning 
many different waste streams. However, even though all preventative actions should be 
taken into consideration when management measures are developed it might be impossible 
to prevent all pollution. First of all if there is no source separation, pharmaceuticals that are 
used will end up in wastewater. Secondly this work discusses only pharmaceuticals, but if we 
take into consideration personal care products that have very different use patterns, then for 
example urine separation is not an answer. To assure effectiveness, risk management 
approaches have to include treatment as well.  
2.3 Treatment approach  
One promising approach to reduce the amount of pharmaceuticals in receiving water 
systems is wastewater treatment. Even though current conventional wastewater treatment 
plants are not designed to reduce pharmaceuticals but rather to treat pollutants like organic 
matter and nutrients, they have (according to recent studies), an ability to reduce the amount 
of certain pharmaceuticals. There are also more advanced technologies that can remove 
these pollutants effectively. The effectiveness of the removal of certain pharmaceuticals 
depends on the treatment process and design and operating parameters of the plant.  
Therefore, it is important to understand how the general treatment process works. 
 
2.3.1 Introduction to the wastewater treatment 
Wastewater treatment is done to reduce the pollutants from wastewater before discharging it 
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to natural water bodies. The constituents of wastewater can create health and environmental 
problems. Wastewater can be evaluated by its characteristics that are three-fold: physical; 
chemical; and biological. The first group includes for example water temperature and 
different solid materials that are flushed with wastewater. The second group includes for 
example total dissolved solids (TDS) that are the solids (residue) that are left after 
wastewater has been filtrated and evaporated. It also includes heavy metals like cadmium, 
copper, lead, mercury, organic material, nutrients (nitrogen N and phosphorous P) and 
pharmaceuticals. The biological characteristics include for example bacteria that can be either 
beneficial or harmful for the treatment process as well as viruses. By analysing these 
characteristics it is possible to evaluate the quality of the wastewater and estimate how 
harmful it is when discharged to the receiving water body. It is also possible to determine 
which harmful substances need to be treated.  This is dependant on the characteristics of the 
receiving water body, since some natural water systems can be more sensitive to for example 
organic matter or nutrients than other water systems. This means that usually the treatment 
requirements are stated according to the sensitiveness of the receiving water system (Drinan, 
2001). 
 
Pollutants in the wastewater can have several negative effects when discharged to the 
receiving water body. When organic matter is released to natural water systems, micro-
organisms start to use it to create energy (micro-organisms use organic matter for example 
for growth and reproduction). They use organic matter by decomposing it, which requires 
oxygen that they take from the receiving water body. If there are large amounts of organic 
matter that is decomposed, the oxygen level of the water (the amount of oxygen that is 
dissolved in water DO) can decrease. Oxygen depletion affects the fauna and flora of the 
water system and it can lead to the situation where large amounts of fish die due to lack of 
oxygen. Heavy metals are important to remove from wastewater since they are dangerous to 
health in general. Nutrients (N and P) cause eutrophication of surface waters when algae and 
water plants use them and overgrow. Eutrophication causes for example massive algae 
blooms and it can create anoxic areas in bottom waters. It can also lead to alteration of food 
chains and this has an effect to the fish stocks (Boesch & al. 2006). It should be noted that 
nutrients in surface waters can have also other sources than wastewater and for example 
fertilizer run-off from agriculture can be a major source. Ammonia is also a source for 
eutrophication and can be toxic for fish and other aquatic organisms. When it is discharged 
to the watercourse it needs a lot of oxygen to oxidise and therefore ammonia oxidizing can 
lead to oxygen depletion in the waterbed.  
Problems that untreated wastewater causes in natural water systems are eliminated or 
reduced by wastewater treatment. Wastewater treatment can be implemented in centralised 
systems in which one plant collects the community’s wastewater through a sewage system. 
After, the treatment wastewater effluent is discharged to receiving watercourse that can be 
for example a river, coastline or a lake. Treatment can be also done onsite where the water is 
used and after treatment water can be released near the place where water has been 
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generated. Onsite treatment, also called decentralised wastewater treatment, has some 
similarities with centralised systems.  
Technology used in conventional wastewater treatment plants has developed from physical 
treatment (when only solid objects were removed from the water) to modern multi-stage 
operation that is currently common in the western world. The wastewater treatment (WWT) 
legislation has been evolving together with technology development. At the moment 
wastewater treatment in Europe is legislated by the European Union and by the States 
themselves. EU is regulating urban wastewater treatment by Council Directive 91/271/EEC 
that was adopted on 21.5.1991. This Directive “concerns the collection, treatment and discharge of 
urban waste water and the treatment and discharge of waste water from certain industrial sectors”. Its 
objective is “to protect the environment from the adverse effects of ... waste water discharges”. The 
Directive regulates, depending on the location of the outflow, wastewater discharges that 
exceed 2,000 population equivalent (p.e.)1. At the moment there is no EU regulation for 
small-scale treatment, but for example both Sweden and Finland have their national 
treatment requirements also for small-scale systems (Council Directive 91/271/EEC).  
In Canada wastewater treatment is regulated by Canadian Environmental Protection Act. 
1999 and the Fisheries Act. According to Canadian Council of Ministers of the Environment 
(CCME, 2008) wastewater is managed at federal, provincial and municipal levels and a 
variety of policies, bylaws and legislation are regulating wastewater treatment. Treatment 
technology used in Canada varies greatly from no treatment (only screening) to state-of-the-
art treatment. Effluent quality and the necessary degree of treatment in federal 
establishments are stated in Guidelines for Effluent Quality and Wastewater Treatment at 
Federal Establishments (EPS 1-EC-76-1, April 1976). The policy is that these regulations are 
always stricter or equal to the standards or requirements of any provincial regulatory agency. 
This means that there can be establishments that are following lower treatment standards, if 
they are not federal establishments. These guidelines state that they do not regulate small 
installations. However the size of a small installation is not defined. 
 
2.3.2 Conventional centralised wastewater treatment process 
Conventional wastewater treatment usually consists of physical, chemical and biological 
treatment steps. The process includes preliminary treatment and the objective is to remove 
different waste solids from the water stream. This is done to prevent these solids from 
disturbing the equipment and the purification process during later steps. Preliminary 
treatment can include various different processes like: screening, grit removal, flow 
equalisations, shredding etc. (Drinan, 2001). 
The first actual treatment step after preliminary treatment is primary sedimentation or the 
primary clarifier. During this step suspended organic solids settle to the bottom of the 
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primary sedimentation tank. Solids that are lighter than water are floating on the surface of 
the water and are skimmed and removed. The second treatment step is biological treatment 
that can be performed in various different ways but the most used is an activated sludge 
system. The alternative for the activated sludge process is the attached growth process. 
During this step, the organic matter and some of the nutrients are decomposed by biological 
processes: nitrification, denitrification and biological mineralisation. Activated sludge 
treatment requires aeration to operate sufficiently (Metcalf & Eddy, 2003; Drinan, 2001).  
After the aeration step, wastewater is settled by the secondary sedimentation process wherein 
the bacteria absorb the pollutants and are removed from the water. This is done so that 
advanced wastewater treatment processes can occur. Advanced treatment is implemented so 
that the purification process can meet the special requirements regarding wastewater 
discharge. There are different processes that are used during advance treatment steps and 
they are selected according to the required purification results. During this step it is possible 
to remove for example nitrogen, phosphorous, soluble chemical oxygen demand (COD) and 
heavy metals. Nitrogen is usually removed by biological nitrification/denitrification process. 
Phosphorous removal is usually done by chemical precipitation. Toxins and heavy metals 
can be treated by membrane processes or by different land application (Schröder & al., 2007; 
Drinan, 2001). 
The concentration of pharmaceuticals is reduced during all of these stages depending for 
example on the type of the pharmaceutical, sludge age which means the time that the 
bacteria is present in aeration process, substrate availability, concentration of oxygen in 
different stages of the process and so on (Larsen & al. 2004). Parameters that influence the 
degradation efficiency of pharmaceuticals are discussed more in detail in the section 2.3.6. 
2.3.3 Strengths and weaknesses of centralised systems 
Treatment in centralised facilities is effective for example because of the more stable 
wastewater flow rate that keeps the biological process more stable. Also it is easier to 
monitor and adjust one big facility than several small ones. For a homeowner, connecting 
property to the common sewage is a care free way to handle wastewaters. Property owners 
do not need to maintain the system or take responsibility for the treatment results.  
In urban areas where there is a lack of space, centralised systems offer an efficient way to 
treat wastewater. Well maintained conventional plants operated by professionals can reach 
good results. Centralised systems usually need to observe the treatment results and report 
them to the authorities hence treatment plants are under the supervision of authorities. 
Even though treatment results are good regarding well-maintained centralised systems, 
overflows, for example, can be a problem. This problem occurs with combined sewer 
systems where both storm water and wastewater are collected to the treatment plant. During 
the heavy rains it might be that the capacity of a treatment plant is not enough and part of 
the storm water and wastewater mix needs to be directed untreated pass the treatment plant 
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strait to the receiving waster system (USEPA, 2008d). 
Guterstam (1997) points out that it is necessary to “create feedback loops of resources from 
wastewater to society” and he claims that ecological demands for wastewater treatment are not 
achieved by using conventional treatment when we consider toxic substances, recycling of 
nutrients and the use of natural resources in general. This means that for example nutrients 
and heat of the wastewater should be used as well. Also the treatment process itself should 
need as less energy as possible. Schröder & al. (2007) claim that: 
“The main aim of applied environmental sciences in the field of wastewater 
treatment has to be the amelioration of the effluent quality from WWTPs 
(Waste Water Treatment Plants) and the enforcement of reliable 
standards of regenerated waters in contact with ground water resources. Only 
hereby will Europe be able to increase the sustainability of drinking water 
resources and contribute in a modest way to decrease effects of global change by 
lowering energy usage, CO2 emission and waste production during wastewater 
treatment.” 
To answer this criticism, an ecological engineering approach has been recommended. This 
would mean that when new technologies are developed, ecological aspects and social 
awareness of different environmental problems should be taken into account (Guterstam, 
1997). According to UNEP (2002) Environmentally Sound Technologies (ESTs); 
“..are technologies that have the potential for significantly improved 
environmental performance relative to other technologies. ESTs protect the 
environment, are less polluting, use resources in a sustainable manner, recycle 
more of their wastes and products, and handle all residual wastes in a more 
environmentally acceptable way than the technologies for which they are 
substitutes.” 
The conclusion of Schröder & al. (2007) is that environmentally sound water treatment will 
include the reduction of greenhouse gasses, recycling materials and development of 
affordable technologies and these should be prioritised. Jenssen & Vant (1997) define 
ecologically sound wastewater treatment as “treatment concepts that promote a high degree of recycling 
as well as minimizing environmental stress”. According to them the two main principles of 
ecologically sound wastewater treatment are 1. recycling and 2. decentralised and onsite 
treatment.  
 
2.3.4 Decentralised wastewater treatment systems 
Concerning risk management and pharmaceuticals in the aquatic environment we have first 
looked into a preventive approach. It was concluded that preventing this pollution reaching 
our watercourses completely may be impossible. Therefore a treatment approach needs to be 
included. Centralised wastewater systems can be an efficient way to treat wastewater but it 
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should be noted that there are large communities for example in Finland, Sweden, Canada 
and the United States that are not connected to centralised wastewater treatment systems 
and that are treating their wastewater onsite. In Finland there are approximately one million 
people, about 20 percent of the Finnish population, living in households that are not 
connected to centralised sewage systems and because of this wastewater has to be treated 
onsite in 350,000 permanent residences and in 450,000 holiday houses (Finnish 
Environmental Institute, 2008). In Sweden there are approximately 500,000 permanent 
residents and same amount of holiday homes that are not connected to centralised 
wastewater systems. In the near future 50-60 percent of these households need to make 
improvements to their systems to be able to meet the requirements for wastewater treatment 
(NUTEK, 2003). In Canada, approximately 25 percent of the residents, 7.5 million people, 
are dependent on decentralised wastewater treatment system (Environment Canada, 1999) 
and in the U.S. approximately 23 percent of the estimated 115 million occupied homes are 
connected to onsite systems (U.S. Census Bureau, 1999). These communities are also 
sources of pharmaceutical pollution. However the role that decentralised systems have or 
can have in risk management is not clear. 
The treatment process in decentralised systems follows the same steps that are used in 
centralised treatment plants. However, usually the advanced treatment steps are excluded. 
The main difference between centralised and decentralised treatment processes is the scale 
meaning that centralised systems can be large facilities treating wastewater from large 
communities when decentralised systems can treat wastewater produced by a single home or 
by a small community. The principle of treatment however is the same. In decentralised 
systems the treatment steps can include settling that is followed by biological treatment. 
According to Venhuizen (1998) decentralised systems are based on the idea that “wastewater 
should be treated (and reused, if possible) as close to where it is generated as is practical.”  
While centralised wastewater treatment plants are operated by a municipality or a company, 
decentralised systems can be used and operated by a single household or a small community. 
Finland’s Environmental Administration recommends that the first step for property owner 
should be to investigate if there is a possibility to connect the property to a centralised 
wastewater sewage system. However if there is no such system available, the second option 
would be to connect several households together and treat wastewater in a small community 
plant. These choices are supported since it is convenient and easy when the property owner 
does not have to worry about the treatment facility or treatment results alone and costs can 
be shared between participants (Suomen ympäristökeskus, 2005). If these two options are 
not available or the costs are too high, the household needs to take care of the wastewater 
onsite. One option is to collect wastewater into a septic tank and when it is filled up, 
transport wastewater to the nearest treatment plant. This however can be quite costly if the 
treatment plant is far away and a lot of wastewater is produced. The second option is to treat 
wastewater onsite. There are various different applications that can be used for onsite 
treatment regarding both single households and small communities. 
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The technology used today in decentralised treatment is based on wastewater’s biological 
treatment that can be combined with chemical treatment. The most used biological 
applications can be divided in two different treatment processes: 
1)       Suspended growth treatment processes (activated sludge process) 
2)       Attached growth treatment processes 
Constructed wetlands and lagoons are also used for wastewater treatment but for example in 
Finland, because of the cold climate, these applications are not common. However where 
the climate is warmer, these applications can be sufficient and cost-efficient choices for 
WWT. Treatment process in lagoons and wetlands follows the natural water purification 
process and is not discussed here in detail (UNEP, 2002). 
There are various models available for decentralised wastewater treatment. The treatment 
process is usually depended on micro-organisms biological processes. In this process micro-
organisms reduce the amount of organic matter and nutrients in the wastewater. Usually the 
first step for wastewater treatment, no matter what model is used, is primary sedimentation 
in a septic tank, where solids and floating scum is separated from the wastewater.  
In an activated sludge reactor the micro-organisms develop sludge where the decomposing 
of the organic matter happens. The reactor is always aerated.  Depending on the retention 
time, also ammonia can be removed by biologically converting it to nitrate nitrogen. 
Phosphorous can be removed by using precipitation chemicals. Sludge reactors can have a 
continuous flow or can treat one batch of wastewater at a time (Sequencing Batch Reactors, 
SBR). According to USEPA (1999) “The difference between the two technologies [conventional 
activated sludge reactor and SBR] is that the SBR  performs  equalization,  biological  treatment, and 
secondary clarification in a single tank using a timed control sequence.” 
Attached growth treatment processes differ from activated sludge process so that the micro-
organisms are attached on the surface of different filling material where they develop a 
biofilm2. In a trickling filter the filling material can be for example rocks, plastic or sand and 
gravel. For example in sand filter the filter media is a bed of sand and gravel that is buried to 
the ground. When wastewater flows through the sand bed, micro-organisms develop a 
biofilm on the surface of soils particles. Micro-organisms of the biofilm start to decompose 
wastewaters organic matter and depending on the retention time ammonia removal occurs. 
Phosphorous is usually precipitated either so that phosphorous adsorbing media is mixed in 
sand or that purified water is collected though drainage system from the sand bed and 
gathered into a precipitation tank where precipitation chemicals are added. 
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There are many different factors that have an effect on what kind of a system is chosen for 
 
2 ”Biofilm:  A colony of bacteria and other microorganisms that adheres to a substrate and is enclosed and protected by secreted slime. Biofilms 
readily form on virtually any surface, whether nonliving or living, where there is moisture and a supply of nutrients. They are important 
components of aquatic and terrestrial ecosystems, typically providing nutrients for small organisms at the base of food chains.” (Martin & 
Hine, 2008) 
 
  
 
the property. For example it is necessary to take into consideration purification 
requirements, the area available for wastewater treatment plant, the slope of the site (is it 
necessary to pump water or can gravity be used), the level of ground water, wastewater 
treatment systems distance to the fresh water source and natural waters like rivers and lakes. 
Also maintenance requirements and costs including both investment and use phase, needs to 
be assessed. 
Even though at the European Union level or in Canada, there are no federal established 
treatment goals for small-scale treatment, Finland and Sweden are regulating decentralised 
treatment plants. In Finland new legislation for decentralised wastewater treatment, the 
Government Decree on Treating Domestic Wastewater in Areas Outside Sewer Networks 
(542/2003), came into force on 1.1.2004. This Decree “sets minimum standards for wastewater 
treatment and the planning, construction, use and maintenance of treatment systems” (Government 
Decree on Treating Domestic Wastewater in Areas Outside Sewer Networks (542/2003), 
Valtioneuvoston asetus 542/2003). The Swedish Environmental Protection Agency has 
stated requirements for small-scale onsite treatment plants and they are very similar with 
Finnish ones. Requirements for treatment are divided in two categories; normal level and 
high level. The basic necessity is that treatment has to be implemented in a way that it does 
not pose a threat to health, living comfort or the environment. Requirement levels for 
Finnish and Swedish small-scale systems are presented in a Table 2-1. (Naturvårdsverkets 
allmänna råd om små avloppsanordningar för hushållsspillvatten (NFS) 2006:7). 
Table 2-1. Treatment requirements for small scale systems in Finland and in Sweden 
Sweden 
% removal requirement 
 
Parameter 
 
 
Finland 
% removal 
requirement 
Normal 
level     
High level 
 
≥ 90 90 90 organic material 
 > 85 70 90 total phosphorus 
(Ptot)  
total nitrogen 
(Ntot) 
> 40  50 
 
 
Finnish reductions are calculated for person-equivalent load that is defined as “the average load 
of untreated wastewater generated by one resident measured as grams per day (g/d), where a person-equivalent 
load of one means the daily load in which organic matter expressed as biological oxygen demand over seven 
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days (BOD7) amounts to 50 g/d, total phosphorus to 2.2 g/d and total nitrogen to 14 g/d.” Swedish 
reductions are calculated for person equivalent load and it is defined almost in the same way 
that in the Finnish Degree. In Sweden the reductions are calculated using following p.e. 
BOD7 amounts to 48 g/d, total phosphorus to 2 g/d and total nitrogen to 14 g/d and daily 
water use is calculated to be 170 l/day (NFS 2006:7). 
Also in Finland when it is justifiable, for example in sensitive areas, the local conditions can 
be taken into consideration and municipalities can have higher or lower requirements for 
reductions. However the main requirement that is stated in Finland´s Environmental 
Protection Act (86/2000) is that “wastewater in areas not connected to any centralized sewerage system 
must be treated so that it does not pollute the environment and there is no risk of pollution”. In both 
countries regulations state only the reduction target for small-scale treatment but it does not 
set requirements for certain technologies. This means that as long as the reduction targets 
are met, households can make their own choices about the technology and way to treat their 
domestic wastewaters. 
According to Environment Canada’s federal discharge guidelines wastewater that is 
discharged to freshwater lakes and low-flow streams, rivers and estuaries, and open coastline 
should have BOD5 less than 5, 20, or 30 mg/l, respectively and ammonia concentration 
should be less than 1.0 mg/l. Total phosphorous should less than 1.0 mg/l. Also in Canada 
municipalities can have stricter discharge requirements (Hu, 2006). 
According to the research done in Finland and in Sweden single family treatment plants are 
able to approach required purification results and there does not seem to be great differences 
between different models. The Finnish research concluded that phosphorous reduction was 
the most difficult to achieve. The best technologies for phosphorous removal were advanced 
sand filter (sand filter including phosphorous precipitation) and Sequencing Batch Reactors 
(SBR). Conventional sand filter (sand filter without phosphorous precipitation) did not 
achieve as good results in phosphorous removal. On the other hand both conventional and 
advanced sand filters removed ammonia and organic matter more effectively than SBRs.  
Both in Finnish and in Swedish studies proper maintenance was highlighted as an important 
factor regarding good treatment result (Vilpas & Santala, 2007; Hu, NUTEK, 2003 ). 
2.3.5 Strengths and weaknesses of decentralised systems 
Venhuizen (1998) points out several communities in the U.S. where it has been concluded 
that decentralised systems are a far more cost-effective choice regarding local conditions. He 
states that in case of a failure for example in pump units or pipelines the environmental 
harm is smaller than it would be with large centralised systems. Decentralised systems are 
usually flexible in a way that treatment facilities can be added to the systems when there is 
growth in population.  There is in contrast to centralised systems which must be designed 
usually with extra capacity to be able to answer to the future treatment needs. One benefit 
for decentralised systems, especially in the areas suffering from water scarcity is that reusing 
treated water for example for irrigation, toilet flushing, car washing etc., is easier since 
treatment is done near water generation and it is not transported out site community. One of 
the benefits when implementing decentralised systems is that there is no need to invest in 
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large collection systems that have only one objective, to transport wastewater. 
However if decentralised systems are not well maintained it can be a source of 
environmental pollution as well as a health hazard. In rural areas where communities are 
dependent on their own water sources, leaking and non-functional treatment applications 
can for example pollute wells. Because of the number of the onsite treatment plants, it might 
be difficult to supervise all the systems. Biological treatment needs stable conditions to 
operate and it can be difficult for example in a single household treatment plant to have a 
stable wastewater flow. This is even more challenging in summerhouses and properties that 
are used only part time. Biological treatment needs time before the treatment efficiency 
reaches the best possible level and this might be a problem if the system is used only short 
periods of time. These challenges highlight the importance of choosing a suitable application 
to a property. 
In conclusion it can be stated that conventional small-scale wastewater treatment plants, 
when well maintained, are sufficient for achieving currently required treatment results. 
However there is no information available about how these applications are able to remove 
organic micro pollutants like pharmaceutical residues. Regulations at the moment do not set 
any requirements on reductions for these substances, but for example in Lund’s commune 
environmental authorities do not exclude the possibility that these requirements can be 
introduced in the future (U. Hedberg-Henriksson, personal communication, 5.3.2008). 
2.3.6 Pharmaceutical residue removal in conventional centralised 
wastewater treatment plants 
Centralised wastewater treatment systems have been criticised because not only are they seen 
as a wasteful way to control water pollution but also because they are not capable of 
removing all PPCPs from the wastewater. For example Schröder & al. (2007) state that 
performance of the state-of-the-art wastewater treatment plants is nowadays not effective 
enough regarding pharmaceuticals.  
This statement is based on the parameters that are considered as relevant by the legislation 
when designing treatment plants. Plants are usually designed to remove organic matter and 
nutrients. Schröder & al. (2007) claim that even though a reduction of organic matter and 
nutrients has had a significant effect in water quality in general, organic micro pollutants like 
PPCPs and endocrine disrupting substances are not targeted at the moment when treatment 
plants are designed. It is true that currently legislation does not include micro pollutants like 
pharmaceutical residues into the treatment requirements. But even though conventional 
treatment plants are not designed to remove for example pharmaceuticals from wastewater 
and they do not have the ability to remove all PPCPs, according to resent studies (e.g. 
Lishman, L. & al. 2006; Servos & al. 2005;  PODEIDON, 2004; Metcalfe & al. 2003) 
conventional treatment plants can remove or reduce the amount of certain pharmaceuticals 
from wastewater. 
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Degradation of pharmaceuticals during WWT process is dependent for example on the 
process used on the treatment plant and chemical properties of the pharmaceutical. 
According to Lishman & al. (2006) depending on the chemical properties the 
pharmaceuticals entering the WWTP can be subject to:   
1) mineralisation to CO2 and water, 
2) retention by the solids portion (sludge/biosolids) if the compound is fat 
soluble, 
3) release to the receiving water either as the original compound or as a 
degradation product. 
Although several studies both from North America and in Europe (e.g. Lishman, L. & al. 
2006; Servos & al. 2005;  POSEIDON, 2004; Metcalfe & al. 2003), provides information 
how different parameters of WWT process affect the degradation of pharmaceuticals, the 
actual influence of such parameters on the efficiency of degradation is not yet fully 
understood.  So far, sludge age (solids retention time and hydraulic retention time), substrate 
availability (substrate inhibition), redox conditions (aerobic, anoxic or anaerobic 
environment), sorption and reactor configuration (for example number of cascaded 
compartments, biofilm growth surface and sand filtration) have been discovered to have an 
affect on pharmaceutical concentration reduction (Larsen & al., 2004). In this study sludge 
age and nutrient removal that is one indication of biofilm growth are discussed more in 
detail. 
One of the most important parameters for pharmaceutical reduction is sludge age. This 
parameter is used to design treatment plants that are based on activated sludge process. 
Sludge retention time (SRT) tells how old the sludge is in the aeration process and in 
addition how long time micro-organisms have time to grow in the system. SRT affects the 
performance of the plant, volume of the aeration tank, how much sludge is produced during 
the treatment and oxygen demand of the process. Different bacteria need different lengths 
of time to grow and for example heterotrophic bacteria that remove organic matter grow 
faster than bacteria that are responsible for nitrogen removal. SRT is dependant for example 
on temperature so that the lower the temperature, the longer the SRT should be to achieve 
the same results. Usual SRT, when just organic matter is the target, is from 5 to 6 days in 
10°C (Metcalf & Eddy, 2003). For example Servos & al. (2005) found out that those plants 
and treatment lagoons with high SRT were very effective in reducing the level of hormones. 
Lishman & al. (2006) reported that removal of diclofenac seemed more efficient when SRT 
was more than 30 day. There was no change in removal efficiency of this drug when SRT 
was less than 15 days. 
 
However not all treatment plants use activated sludge process. According to POSEIDON 
(2004) also biofilters seem to reduce certain pharmaceuticals from wastewater if the system 
reaches the same nutrient removal as activated sludge system. Observations of Servos & al. 
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(2005) support this by stating that it appears that centralised plants that are well operated and 
which also achieve nitrification tends to have a higher removal of estrogens. Therefore in 
this study it is assumed that if a treatment system has an ability to remove ammonia from 
wastewater (nitrification), it can also remove certain pharmaceuticals. However linkage 
between pharmaceutical removal and nitrification has not been yet fully studied or 
understood. 
 
Ammonia is removed from wastewater usually by using biological nitrification. During this 
process certain bacteria are used to convert ammonia to less harmful compounds. 
Nitrification is a two step microbiological process. During the first step ammonia (NH4-N) is 
oxidised to nitrite (NO2-N) and during the second step nitrite is oxidised to nitrate (NO3-N). 
Oxidation is done by nitrifying bacteria so that during the first step it is done by ammonia-
oxidising bacteria (AOB) and during the second step nitrite-oxidising bacteria (NOB) 
(Siripong & Rittmann, 2007).  
  
1. step:  
  2NH4+ + 3O2 → 2NO2- + 4H2O...................................................(2.1) 
2. step: 
  2NO2-+ O2 → 2 NO3- ......................................................................(2.2) 
Total oxidation reaction: 
   NH4+ +2 O2 → N O3-+ 2H+ + H2O.............................................(2.3) 
As we can see from the equations above, nitrification process needs the presence of 
dissolved oxygen. Nitrifying bacteria need also carbon source, phosphorous and trace 
elements like calcium, copper, zinc etc. for growth. The nitrification process is sensitive to 
various factors like low temperature, extreme pH and different chemical inhibitors. Low 
temperature can be a problem of course in Nordic parts of the world but also heavy rains 
can lower the process temperature if combined sewage system is used. Optimal pH 
according to Metcalf & Eddy (2003) is in the range from 7.5 to 8.0. As we can see from the 
nitrification equation, during the nitrification process hydrogen ions H+ are released. This 
means that the nitrification process itself makes the environment more acidic. Therefore the 
process might need adjustment, for example addition of lime. Nitrifying organisms are 
sensitive also to a wide range of organic and inorganic compounds hence they are good 
indicators of the presence of toxics already at low concentrations. Toxic compounds include 
for example solvent organic chemicals, amines, tannins, proteins, alcohols etc. These toxins 
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can inhibit nitrification or even kill the nitrifying bacteria (Metcalf & Eddy, 2003). 
In some wastewater plants nitrification is followed by denitrification, a process where 
bacteria convert nitrate to nitrogen gas (N2) in an anaerobic environment. However 
denitrification is not within the scope of this study.
Even though conventional wastewater treatment systems cannot remove all micro pollutants 
from wastewater, for example novel membrane techniques and ozonation with or without 
urine separation have shown potential. According to POSEIDON (2002) ozonation is a 
good post treatment step and it can be recommended if wastewater is reused. Ozonation is 
considered to be rather cheap but highly energy consuming process. This might limit 
possibilities to apply this technology. Reif & al., (2007) reported a high reduction for 
ibuprofen and naxproxen by using a membrane bioreactor (MBR). Diclofenac was removed 
less than 10 percent. This technology is used in activated sludge process so that membrane 
separates active biomass and treated wastewater. Similar reduction results have been 
reported also using conventional treatment processes (Lishman & al., 2006; POSEIDON, 
2004). In addition there are highly effective membrane technologies for example reverse 
osmosis, but the costs for this kind of a treatment are high (Metcalf & Eddy, 2003). Schröder 
& al. (2007) criticise high costs and maintenance requirements of these advanced 
technologies and he points out that there is a possibility that these techniques are adopted 
only by wealthier countries and even then they are used only in large scale wastewater 
treatment plants. 
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3 Case study: Recirculating Biofilter (RBF) 
 
 
In order to assess the viability of decentralised wastewater treatment as a risk management 
tool, a recirculating biofilter (RBF) (decentralised wastewater system), was selected for a case 
study. Since there was no information available on pharmaceutical degradation and 
decentralised wastewater systems it was important to test if it was possible to remove 
pharmaceuticals from wastewater and thereby contribute to the understanding regarding the 
role of decentralised systems in risk management. Since this was the first study to look into 
this issue using a RBF it was necessary to do the experiments in laboratory conditions. As 
mentioned earlier, regarding centralised systems there are different parameters and 
operational characteristics that affect the pharmaceutical removal efficiency. One of these 
characteristics is nutrient removal. In this case study both RBF nitrification efficiency and 
the ability of pharmaceutical removal were tested. 
 
RBF has been scientifically studied before regarding for example BOD removal (Hu, 2006) 
and nitrification and denitrification efficiency (Farzana, 2008). These studies offer a 
background for experiments performed with pharmaceuticals and they provide the 
possibility to compare results of this study with previous results. 
  
 
3.1 Recirculating Biofilter as a treatment application 
Recirculating biofilters use sand, gravel or other media to treat settled wastewater. Treatment 
application includes a septic tank and a filter bed that can be lined and excavated to the 
ground.  During the treatment settled wastewater flows from the septic tank to recirculation 
tank. From the recirculation tank wastewater is dosed though distribution network onto the 
surface of a filter bed. Wastewater percolates through the filter bed and it is gathered 
through under drain collection systems. Part of this water is then re-circulated to the 
recirculation tank and part of it is discharged from the treatment system (treated wastewater 
effluent). Feeding frequency onto the filter bed is usually 1 to 3 times per hour and typical 
recirculating ratios are between 3:1 and 5:1 (United Sates Environmental Protection Agency 
(USEPA), 2008e). A schematic flow diagram for recirculating biofilter is presented in Figure 
3-1. 
 
31 
Hannamaria Yliruusi, IIIEE, Lund University 
 
Figure 3-1. Schematic flow diagram for a recirculating biofilter (RBF). (Source USEPA, 2008c) 
RBF treatment is based on microbial processes. Microorganisms form biofilm on the surface 
of the filter media and they absorb soluble and colloidal waste material (organic material and 
nutrient) in the wastewater. Absorbed materials are then either used to build new cell mass 
or they are degraded to CO2 and water. Most of the treatment occurs on the surface of the 
filter media bed (approximately 15 cm of the filter depth). In this top layer suspended solids 
(SS) and BOD are removed. It is stated that BOD is possible to remove almost completely 
with sufficiently long retention time. Nitrifying bacteria are located deeper in the filter media 
(USEPA, 2008e). 
 
Recirculation of wastewater provides some advantages compared to the single-pass filter. It 
minimises odours and improves BOD and total suspended solids (TSS) treatment (Hu, 
2006). It is also possible to use higher hydraulic loading rate (HLR) when recirculation is 
included. Hydraulic loading rate determines wastewater retention time in filter media. 
According to USEPA (2008e) depending of the filtering medium size, HLR ranges from 0.12 
to 0.24 m3/m2/day. 
 
RBF has shown good ability to remove BOD, TSS and total nitrogen (TN). Usually BOD 
and TSS effluent concentrations are less than 10 mg/l and nitrification is usually complete 
(except in severely cold conditions). Recirculation tank promotes natural denitrification 
which can result 40 to 60 percent removal of TN. Chemical absorption of phosphorous is 
limited by the characteristics of the filter media and chemical precipitation might be 
necessary if phosphorous removal is included to the treatment requirements (USEPA, 
2008e). 
 
 
Recirculating biofilter is a flexible application. It can be used for both single households and 
small communities. According to USEPA (2008e) RBFs are “Extremely reliable treatment 
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devices.” and they are resistant to flow variations. Since RBFs can use higher hydraulic loading 
rates than for example a systems including septic tank and conventional percolation area, the 
footprint required for the treatment can be reduced. RBFs can use various different filter 
media materials depended on what is locally available and studies have shown that crushed 
glass is a good alternative for silica sand and that geotextile has a potential (Farzana, 2008; 
Hu & Gagnon, 2006). 
 
Hu (2006) points out that crushed glass has several advantages when it is compared to silica 
sand. He states that crushed glass is less expensive and that is has an environmental 
advantage since crushed glass is recycled product. Also since crushed glass can be pulverised 
into different sizes for specific design requirement, when sand is sieved for specific sizes, it is 
considered to have an advantage. These advantages however might be depended on local 
conditions. It might be for example that there is no glass recycling scheme implemented, or 
that there is sand available locally with a low price. There are several factors that can affect 
to the environmental performance of a product and without further research; it is hard to 
state that crushed glass has an environmental advantage. According to Hu (2006) by Loomis 
& al. (2004) textile filters can also have an advantage when they are compared to natural 
media filters. This is because of the smaller foot print required for the treatment (higher 
HLR can be used) and lightweight compact design.  
 
Like any other treatment application also RBF needs to be constructed carefully according to 
design specifications and it needs to be maintained sufficiently. Regular maintenance on RBF 
includes inspection of the pressure head in the end of the distribution systems. Also lines 
need to be cleaned (drained and brushed) at least once per year. Recirculation pumps and 
controls need to be inspected and calibrated and the surface of the filter media unit needs to 
be scraped and cleared from vegetation. Recirculation tank needs to be observed for sludge 
accumulation and sludge is good to remove one to three times per year (USEPA, 2008). 
 
3.2 RBF bench scale setup 
The RBF system setup has been presented in the Figure 3-2. Raw wastewater (system 
influent) was first put into to the septic tank from where it was pumped to the recirculating 
tank. From recirculating tank wastewater was pumped by the second pump to the biofilter 
columns where wastewater travelled through the columns. Biofilter effluent was gathered to 
the biofilter effluent tank where the water was divided into two parts. Four units of the 
water volume were circulated to the recirculation tank and one unit of the biofilter effluent 
was discharged to the RBF system effluent tank (treated wastewater). Wastewater was fed 
into the system at a constant frequency and feeding was controlled by a computer based 
pumping and timing system. Based on the previous studies by Hu (2006) and Farzana (2008) 
the feeding frequency was selected to be 96 times per day. The pumping frequency was 
structured in cycles that were 15 minutes long. During one cycle pumps were operating first 
4 minutes after which there was 11 minutes long recess.  
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During the experiment time two trials were done. During the first trial there were five 
parallel treatment lines as described in Figure 3-2 and during the second trial six parallel 
treatment lines. During the second trial bench scale system was modified so that the pump 
that was pumping system effluent from biofilter tank to the effluent tank was removed and 
the system effluent was gathered to the biofilter tank. Pumps that were used in the system 
were not designed to operate in such a low flow (minimum 1 ml/4 minutes) and this caused 
problems during the trial. Eliminating one pump from the system helped to guarantee 
effluent for sampling. 
 
 
Effluent 
Pump 
Pump Air vents on the 
filter column 
cover 
Gravel
Filter Media
Effluent Tank 
Septic Tank Recirculation Tank
 
Figure 3-2. RBF system setup. (Source Hu, 2006) 
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Figure 3-3. Biofilter columns different media combinations. (Source Hu, 2006) 
Biofilter columns (Ø 2.5 cm, total length 24 cm) were filled with filtermedia (15 cm of the 
total length). During the first trial both crushed glass (CG) and geotextile (GT) were used as 
single filter media but also as combinations (dual filter media) in a following way:  
• 1. column: 100 % crushed glass (CG:GT 4:0), 
• 2. column: 75% crushed glass and 25 % geotextile (CG:GT 3:1),  
• 3. column: 50% crushed glass and 50 % geotextile (CG:GT 2:2),  
• 4. column: 25% crushed glass and 75 % geotextile (CG:GT 1:3), and  
• 5. column :100 % geotextile (CG:GT 0:4). 
Volume ratios for different columns are presented in Figure 3-3. Different filtermedia 
combinations were selected based on the previous studies by Farzana (2008). Filter media 
was supported in the column by bottom gravel bed which helped to avoid clogging of the 
columns. Air circulations and aerobic conditions within the filter beds were secured by 0.5 
cm-diameter holes on the caps of the columns. Columns were covered with aluminium foil 
to avoid the contact with sunlight and so to prevent photosynthesis process if any algae 
should grow in the system. Calculations regarding geotextile filter volume are presented in 
Appendix II. 
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Like the filter columns all the tanks were also covered with aluminium foil and both the 
septic tanks and recirculating tanks were sealed with parafilm and foil to simulate the 
conditions of the field plant. Water balance and loading rates for the system were calculated 
using experiences from previous studies and following USEPA (2002e) recommendation. 
Calculations about water balance in detail are presented in Appendix II. RBF system was 
operated in a room temperature which was measured to be between 21 and 23ºC during the 
experiments.  
As mentioned RBF system was examined during two different trials. During the first trial the 
systems (all five parallel treatment lines) were fed with raw wastewater3. All treatment lines 
were installed with different biofilter column as they are presented in Figure 3-3. The 
purpose of the first trial was to first study biofilm growth and observe the time for the 
biofilters to reach a steady stage (ammonia removal is steady). Second purpose was to study 
nitrogen removal efficiency of different biofilter media. Biofilm growth was monitored by 
analysing the concentration of ammonia both from system influent and systems effluent. 
When according to the laboratory analysis, ammonia concentration of the effluent was less 
than 10 mg/l, it was assumed that biofilm had developed into the filter media and that the 
filter was nitrifying. 
Based on the results of the first trial one filter media (100 percent of crushed glass, (CG:GT 
4:0) ) was selected for the second trial. During the second trial similar filter media was used 
in all six biofilter columns. Crushed glass filter was selected since it appeared that it removed 
ammonia most efficient during the first trial. 
During the second trial first all the six treatment lines were fed with raw wastewater to grow 
biofilm to the filter media. When biofilters reached the steady stage raw wastewater was 
changed to treated wastewater4 and pharmaceutical feeding to the system started. Treated 
wastewater had a lower amount of solids which made it easier to run the bench scale system 
(less clogging). However according to the laboratory analyses, ammonia level of the influent 
stayed on the same level during both trials (see Figure 3-6). The first two treatment lines 
(biofilter columns 1. and 2.) were fed with mixture of treated wastewater and ethanol that 
included gemfibrozil. The second two treatment lines (columns 3. and 4.) were fed with 
treated wastewater and ethanol that included a mixture of four different pharmaceuticals:  
gemfibrozil, naproxen, diclofenac and ibuprofen. The last two treatment lines (columns 5. 
and 6.) were used as control filters and these lines were fed only with treated wastewater. 
Pharmaceutical solutions were made in methanol since the solutions were above solubility of 
these drugs. The final concentration of pharmaceuticals in the wastewater was 200 μg/l. It 
should be noted that concentration used in this research is higher than concentrations that 
have been observed in field studies. Higher concentration was used to make sure that it was 
possible to track pharmaceuticals using available pharmaceutical analyses. 
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3 Wastewater was gathered from Mill Cove Wastewater Treatment Plant Bedford, Nova Scotia, Canada. 
4 Treated wastewater was gathered from Mill Cove Wastewater Treatment Plant Bedford, Nova Scotia, Canada. 
 
  
 
The raw wastewater used in the experiments was gathered from Mill Cove Wastewater 
Treatment plant during three separate times and kept refrigerated. Samples were taken 
during the first trial from influent, recirculating tanks and effluent tanks and they were 
analysed for pH, ammonia (NH4+-N), nitrate nitrogen (NO3--N), total nitrogen (TN) (which 
is the summation of ammonia nitrate and organic nitrogen). The first trial lasted 16 days and 
during that time samples were taken six times. The second trial lasted 24 days and during 
that time samples were taken nine times.  
Samples were analysed using standard methods. Ammonia was measured with 8038, HACH 
DR/2500 Spectrophometer. Nitrate nitrogen was measured with method 8039, HACH 
DR/2500 Spectrophometer. Total nitrogen was measured with 10071, HACH DR/2500 
Spectrophometer (HACH DR/2010 Spectrophometer Handbook). The pH was measured 
by the Orion Model 230A pH meter.  
In addition to the analyses that were done during the first trial, during the second trial the 
concentrations of four pharmaceuticals were analysed both from the influent and the 
effluent regarding all six parallel treatment lines. Analyses of pharmaceuticals were done for 
five samples sets. Pharmaceuticals were analysed using Solid Phase Extraction Procedure 
(Krkosek, 2006). All laboratory analyses were performed at the Dalhousie University Centre 
for water Resources Laboratory. 
3.3 The results of RBF bench scale system experiments 
3.3.1 Ammonia removal efficiency using different biofilter media's 
During the first trial it was examined how different biofilter media could remove ammonia. 
According to the laboratory analyses RBF bench scale system reduced ammonia effectively. 
During the experimentation the ammonia concentration was higher in raw wastewater and in 
recirculation tank than in system effluent. After 16 days, ammonia concentration in RBF 
effluent in the Column CG:GT 4:0 was close to 0,0 mg/l and the biofilter had reached a 
steady stage. Other columns showed similar results except the Column CG:GT 0:4 that 
removed ammonia only slightly.  
 
Figure 3-4 shows ammonia concentration variation in time for the raw wastewater (system 
influent) and for the system effluent from the biofilter column CG:GT 4:0. 
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Figure 3-4. Ammonia concentration for the system influent and for the systems effluent from the 
biofilter column 100 % crushed glass. 
Concentration of nitrate increased in time in all column systems except in the Column 
CG:GT 0:4. This indicates that when biofilters started nitrification and as ammonia was 
converted to nitrate the concentration of ammonia reduced and concentration of nitrate 
increased. Since the Column CG:GT 0:4 was not nitrifying, the concentration of nitrate 
stayed low. 
Total nitrogen (TN) concentration varied during the first trial both in raw wastewater and in 
all samples taken from recirculating- and RBF system effluent tanks. The total amount of 
nitrogen compounds should remain the same before and after nitrification reaction. This 
means that the concentrations of TN should be similar in both effluent and influent. 
However results shows that TN concentration reduces when wastewater has been treated in 
the system. This indicates denitrification; nitrate was converted to nitrogen gas (N2) that 
escaped the system through ventilation holes of the column caps. Denitrification is a benefit 
for the RBF systems since even though ammonia removal has been considered to be most 
important, reduction in nitrate reduces eutrophication in the receiving water system. Figure 
3-5 presents TN concentrations of influent and effluent for the column CG:GT 4:0. 
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Figure 3-5. Total nitrogen concentration of the system influent and effluent from the biofilter column 
100 % crushed glass 
pH varied during the first trial in raw wastewater, recirculating tank effluent and in RBF 
system effluent. All the columns showed similar results. After couple of days pH was slightly 
lower in RBF system effluent tanks than in recirculating tanks. This also indicates 
nitrification since when ammonia is converted to nitrate H+ ions are released and these ions 
make water more acidic. 
3.3.2 Pharmaceutical removal efficiency 
During the second trial pharmaceuticals were added to treated wastewater and the mixture 
was fed to the system. Gemfibrozil was added to the first two Columns (1. and 2.), and a 
mixture of gemfibrozil, naproxen, diclofenac and ibuprofen was added to the Columns 3. 
and 4. Columns 5. and 6. were feed with treated wastewater without additional 
pharmaceuticals. 
Ammonia concentration was analysed as it was during the first trial. Figure 3-6 presents 
ammonia removal of the first column that was filled with 100 percent cursed glass during 
both trials. The red arrow shows the time when second trial started and pharmaceuticals 
were started to add to the system. To this column only gemfibrozil was added. As it shows in 
the Figure 3-6 the concentration of ammonia in the influent seems to be higher that it is in 
the system effluent. The same figure shows that the concentration of ammonia in the 
influent varied during the experiment time. However we cannot see a great difference 
between concentrations of ammonia during the first trial when raw wastewater was used and 
during the second trial when treated wastewater was used. 
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Figure 3-6. Ammonia concentration of influent and effluent in the biofilter that was filled with only 
crushed glass and the time line for first and second trial 
The other biofilters showed similar behaviour regarding ammonia removal. This gives 
indications that nitrification was in process in all biofilter columns. 
According to the laboratory analyses the average removal of gemfibrozil, naproxen and 
ibuprofen was more than 90 percent. Diclofenac was removed by average approximately 70 
percent. 
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Figure 3-7. % removal of gemfibrozil, naproxen, ibuprofen and diclofenac in the biofilter columns 3. 
and 4. 
Regarding both ammonia removal and pharmaceutical removal, statistical analyses were 
performed. Paired t-test was used to compare the average influent and effluent 
concentrations. Statistical analysis demonstrated (with 95 percent confidence) that there was 
a difference in the influent and effluent ammonia concentrations regarding all six parallel 
treatment lines. The paired t-test regarding pharmaceutical reduction demonstrated (with 95 
percent confidence) that there was a difference in the influent and effluent pharmaceutical 
concentrations regarding all five examined pharmaceuticals. Also a 95 percent confidence 
interval was constructed and results are presented in the Figure 3-7. The observed reductions 
in pharmaceuticals are statistically significant. 
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4 Discussion 
Several studies prove that there are more than 80 different pharmaceuticals and 
pharmaceutical metabolites found in water sources and wastewater influents and effluents 
(Herberer, 2002). Even though current understanding among the scientific community 
seems to be that pharmaceuticals do not have an acute affect on human health (Breitholtz & 
Bengtsson, 2006; Schwab & al. 2005; Christensen, 1998), there are indications that these 
pollutants are harmful for other organisms. Studies have found that these chemicals have an 
effect on some aquatic organisms for example fish (Gross-Sorokin, Roast, & Brighty, 2006) 
and that some aquatic species are likely to accumulate pharmaceuticals (Redshaw & al., 2008; 
Gagné, 2007). There seems to be consensus that there is uncertainty regarding the fate of 
pharmaceuticals in the environment, the effects of these substances on lower trophic level 
organisms, the long term effects regarding both humans and the environment, and what are 
the effects of mixtures of different Pharmaceuticals and Personal Care Products (PPCPs) 
(Enick & Moore, 2007; National Water Research Institute (NWRI), 2007; Cleuvers, 2002).  
We have procedures like Environmental Risk Assessment (ERA) to assess environmental 
risks of pharmaceuticals, however they need to be further developed (Environmental Risk 
Assessment of Pharmaceuticals (ERAPharm), 2008) since at the moment ERAs include 
various assumptions. For example the ERA procedure looks into acute effects of substances; 
however we should also be interested in chronic effects. To compensate for this, different 
assessment factors are used during the ERA process. Here the question arises: Do these 
assessment factors represent our values? How should we interpret these assessments? 
Bodansky (1994) has stated: 
‘‘Risk assessment,  unlike  the  precautionary  principle,  generally assumes  
that  we  can  quantify  and  compare  risks.  It is information intensive and 
rational.  Moreover, it can and often does take a neutral attitude towards 
uncertainty. (..) In contrast, the precautionary principle is not neutral towards 
uncertainty—it is biased in favor of safety.”   
Even though risk assessment is "information intensive and rational" we have to deal with data 
gaps mentioned before. Tallacchini (2005) points out that since there are so many 
uncertainties regarding ERA:  
“The  prospect  inherent  in  the  precautionary principle tends to reduce as 
much as possible the mistakes that produce risks for people, considering that it 
is better to make a mistake harmful to the economy  – a mistake that limits 
development not risky in itself – but not harmful to people”. 
  
It seems that even though we do not have full scientific proof about the risk level that 
pharmaceutical residues represent in the aquatic environment, governments are 
implementing the precautionary principle and they are already looking into different risk 
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management alternatives (NWRI, 2007; Assessment of Technologies for the Removal of 
Pharmaceuticals and Personal Care Products in Sewage and Drinking Water Facilities to 
Improve the Indirect Potable Water Reuse (POSEIDON), 2004). In Canada a list of 
priorities has been developed that guides of research regarding PPCPs and an environment. 
This list contains 1) suggestions of what issues should be considered when effects of PPCPs 
are examined, 2) proposals for developing a monitoring network and 3) proposals for 
developing approaches for risk management.  
Efficient risk management includes both preventative and treatment alternatives. Further, 
these two alternatives include various different measures. In this study preventative measures 
like source control, source separation and raising awareness have been discussed. These 
measures can be implemented using different management tools. For example, source 
control can be implemented by reducing pharmaceutical consumption or providing take-
back programs for pharmaceutical residues. Since it is impossible to prevent pollution fully, 
efficient risk management includes also treatment alternatives. Regarding pharmaceuticals in 
wastewater it is quite natural to look into our current infrastructure and to examine how we 
can use our already existing wastewater treatment facilities when dealing with these 
compounds. Various different studies has addressed how effective our conventional 
centralised wastewater treatment plants are reducing pharmaceuticals (e.g. Lishman, L. & al. 
2006; Servos & al. 2005; PODEIDON, 2004; Metcalfe & al. 2003). The results have been 
encouraging since some pharmaceuticals can be removed or the amount can be reduced with 
conventional treatment. 
Wastewater can be treated in centralised units or in smaller scale onsite treatment plants. 
Figure 4-1 presents different risk management approaches. To be able to gain deeper 
understanding about the risk management choices that we have we need to also look into 
decentralised wastewater treatment. It seems however that regarding PPCPs this subject has 
been less researched than centralised systems.   
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Figure 4-1. Different risk management approaches. 
Because there was no information available about decentralised system's capacity to remove 
pharmaceuticals, it was necessary to research this area by experiments. To be able to 
determine the role that decentralised wastewater systems can have regarding risk 
management, the pharmaceutical removal effectives of Recirculating Biofilter (RBF) was 
evaluated. The main objective of laboratory tests was to study if a bench scale nitrifying 
biofilter is capable of removing four selected pharmaceuticals (gemfibrozil, naproxen, 
ibuprofen and diclofenac). During the experiments both ammonia removal and 
pharmaceutical removal were observed.  
During the first trial ammonia, removal of five different filter materials was compared. 
According to laboratory analyses the average concentration of ammonia in the influent was 
32 mg/l. After the system reached the steady stage (16 days from the start up), the average 
concentration of the ammonia in the effluent for the filter column that was 100 percent 
crushed glass CG:GT 4:0 was 0,28 mg/l achieving  99 percent removal efficiency. This result 
is consistent with Farzana (2008), Hu & Gagnon, (2006) and USEPA (2002e). The biofilter 
column CG:GT 4:0 showed slightly better ammonia removal results during the first trial than 
the other filters. The filter column that had only geotextile (CG:GT=0:4) as filter material 
did not reach the steady stage as fast as others since after 16 days there were no indications 
of nitrification.  
Based on the results of the first trial, crushed glass was used as the biofilter media during the 
second trial. Six biofilters were dosed with the mixture of treated wastewater and 
pharmaceuticals. According to laboratory analyses, ibuprofen, gemfibrozil and naproxen 
were removed more than 90 percent. Diclofenac was removed approximately with 70 
percent efficiency.  
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It seems that pharmaceuticals studied in this thesis are not studied in RBF systems before. 
However there are studies that have been looking into how centralised treatment plants are 
capable of reducing these substances. Also some other laboratory studies have been done. 
According to research performed by the EU project: POSEIDON (2004), in nutrient 
removing plants it was possible to remove more than 95 percent of ibuprofen. Lishman & 
al.(2006) reported 91-98 percent removal efficiency in centralised treatment plants for 
ibuprofen and 79-98 percent removal efficiency for naproxen and in a number of cases it 
was not possible to measure concentration of these two from effluent indicating 100 percent 
removal. Reif & al. (2007) reported similar removal results regarding ibuprofen and 
naproxen (more than 90 percent removal) by using pilot scale membrane bioreactor (MBR).  
According to Reif & al. (2007) they reached less than 10 percent removal of diclofenac by 
using pilot scale MBR. Lishman & al.(2006) reported that gemfibrozil median reduction was 
66 present and data for diclofenac showed several negative reduction values the median 
reduction being – 34 percent regarding centralised WWTP. These negative results were not 
explained in the study but it might be that since it seems that diclofenac is very persistent it 
can bind to sediment particles and might then be released again to water when for example 
sludge is removed from the treatment system. Also there might be some problems when 
measuring influent and effluent since it can be difficult to be able to measure exactly the 
same particles that go through the systems. According to Heberer (2002) gemfibrozil had 
shown 17 percent removal efficiency in the municipal sludge treatment plant (STP) but he 
also states that Ternes (1998) has reported a removal of 69 percent for the same 
pharmaceutical in the STP. 
Laboratory results of this thesis cannot be compared as such with results from previous 
studies and one must be careful when interpreting results. First of all the scale of the 
treatment systems can have an effect on how effective the removal of compounds is. Also 
the treatment technology can be different. However it can be said that it seems that 
reduction of ibuprofen and naproxen seems to follow the same scale in this research as it has 
been presented regarding centralised treatment systems. But regarding gemfibrozil and 
diclofenac there are differences between literature and laboratory results of this research. 
The removal of gemfibrozil seems to vary in the literature and laboratory results of this study 
are more close to results of Ternes (1998). Also the difference in diclofenac removal 
between previous studies and laboratory experiments for this research seems substantial and 
cannot be explained based on this research.  
As stated, there are limitations when interpreting the results of the laboratory experiments. 
In laboratory environment conditions can be controlled and this can affect the results. For 
example experiments were performed in steady room temperature (21-23 °C) and it is 
known that nitrification process is sensitive to temperature (Metcalf & Eddy, 2003). This 
means that for example RBF nitrification performance on field conditions can be different 
and this might affect the pharmaceutical removal. Even though regarding literature 
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(POSEIDON, 2004; Servos & al., 2005) there are indications that treatment plants that 
remove nutrients also remove pharmaceuticals, based on this research it cannot be stated if 
there is a connection between ammonia removal and pharmaceutical removal. This means 
that it is not known if the biofilter would have removed pharmaceuticals also if nitrification 
would had been inhibited.  
For laboratory experiments influent was gathered from a centralised treatment plant. It 
might be that wastewater characteristics are different in decentralised systems and so they 
can effect to the treatment results. Also because of the analysing methods it was necessary to 
use higher concentrations of pharmaceuticals in the influent than are reported in the 
literature. Therefore it might be that the removal efficiency is different with lower 
concentrations. 
Even though, based on this research, it cannot be stated that decentralised systems have a 
similar ability to remove pharmaceuticals than centralised systems have, it seems that there is 
potential and further research is needed. Even though at the moment there are no treatment 
requirements for pharmaceuticals, it is possible that in the future treatment requirements will 
also include certain micro pollutants. If these requirements are going to be part of a policy it 
is important to know if we have technical possibilities to achieve requirements in a cost-
efficient way. 
If future studies show that decentralised systems have the same ability regarding 
pharmaceutical removal as centralised systems, it will be important for communities where 
decentralised systems are the cost-efficient option. It would mean, for example, that we 
could enhance the use of decentralised systems since the difference regarding pharmaceutical 
removal would not be substantial when compared to centralised systems. If however, future 
research shows that decentralised systems do not reach the same level in pharmaceutical 
removal and risk management is needed, preventative alternatives would have an important 
role regarding rural areas. This would mean that for example urine separation could be used 
as one of the management measures since this kind of a technology might be easier to apply 
in rural areas than in cities where we can have old and inflexible infrastructure. Regarding 
urine separation it should be noted that biological treatment needs nutrients to operate well 
and this should be considered when applying separation 
If in the future, when we have a more specific picture about the risk level, it is necessary to 
apply risk management measures, it seems that in general, the most efficient way to use risk 
management tools is to combine preventative and treatment measures. Local conditions, 
treatment needs, costs, available technology etc., needs to be considered when risk 
management choices are selected.  
When we have more knowledge about which pharmaceuticals we can treat from our 
wastewater, we can focus our prevention measures to most harmful substances that are not 
treatable.  The pharmaceutical industry can look for alternative compounds or we can 
inform consumers about the impacts of the drug and highlight proper disposal. 
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It is also important to recognise the need to operate and manage wastewater treatment 
processes in a sufficient way regarding both centralised and decentralised systems. This 
seems to benefit nutrient and BOD as well as pharmaceutical removal. Since there seems to 
be a connection between pharmaceutical removal and nitrification, it might be possible to 
reduce the amount of pharmaceuticals in wastewater without specific reduction requirements 
targeted to pharmaceuticals. Instead we could still focus on nutrients. For example regarding 
wastewater and treated wastewater used for laboratory experiments for this thesis, there was 
no difference in ammonia concentrations. Knowing this we can state that there are problems 
regarding plants activated sludge process and the main focus for this plant leys somewhere 
else than in micro pollutants. 
There are many factors that affect which pharmaceuticals and how much of them are found 
in wastewater. These include for example the volumes of that drugs that are used, use 
patterns, how well they metabolise, what kind of treatment technology is used and how 
much water is used. These factors are very different between different countries and so 
concentrations of pharmaceuticals in the wastewater can differ in different regions (Lishman 
& al., 2006; Metcalfe & al., 2003). This should be recognised when management alternatives 
and policy directions are assessed. One tool that works in Scandinavia might not be useful in 
Canada and so efficient risk management measures should be selected considering these 
differences and local conditions. 
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5 Conclusions and recommendations 
 
5.1 Conclusions 
We have scientific evidence that there are traces of pharmaceuticals in our groundwater, 
drinking water and watercourses. Since this discovery, it has been necessary to study if these 
substances are representing a threat to human health and to other organisms. Evaluation of 
the risk level needs to be done in a systematic and scientifically sufficient way understanding 
also the economic limitations and the context of the risk assessment. Risk assessment tools 
have been developed both in Europe and in North America and the objective of these tools 
is to help us to focus research and also risk management measures to the most critical 
environments, organisms and chemicals.  
So far it is known that the present levels of pharmaceutical residues do not represent an 
acute threat to human health but there is a reason to believe that other organisms in the 
aquatic environment suffer from this pollution. What is not yet known is how these 
chemicals affect humans and the environment in the long run and what affects different 
combinations of different substances might have. Since there are many uncertainties 
regarding pharmaceuticals in the environment it is necessary to consider implementing the 
precautionary principle (PP). Adapting this approach means that when we interpret 
environmental risk assessments, we take into account the assumptions that are done when 
performing the assessment. When evaluating results we have to consider if the context of the 
assessment has been integrated into the assessment and does it represent the values like the 
PP.  If the assessment does not include these, we should be aware of this when concluding 
which actions should be taken. 
Applying the precautionary principle means that we cannot wait for full scientific proof on 
the level of the risk. It is important to first assess how we are able to prevent these 
compounds from reaching the environment, and second to assess measures to eliminate or 
treat these pollutants. Based on different choices we have, it is possible to act and to reduce 
the potential adverse effects and thereby to reduce the risk.  
This study looks into different possibilities that we have regarding risk management of 
pharmaceutical residues in the wastewater and researching what role treatment and more 
specific decentralised wastewater treatment could have as a risk management tool. The 
overall goal for this research was to contribute to the general understanding regarding risk 
management measures for pharmaceuticals in the aquatic environment. To reach this 
objective, two research questions were tested: 
 
1) How can we manage environmental risks regarding pharmaceutical residues in 
wastewater? 
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• What role can decentralised wastewater treatment have as a risk 
management alternative? 
2) How effective is nitrifying Recirculating Biofilter (RBF) for reducing four selected 
pharmaceuticals from wastewater? 
In this study different risk management measures have been assessed and both preventative 
and treatment approaches have been look into. Pollution prevention measures include for 
example raising awareness of all stakeholders about the environmental effects of 
pharmaceuticals. Different stakeholder groups need different types of information. For 
example in Sweden this has been acknowledged when models about drug categorisation have 
been developed. Targeting information to different groups, it is possible to activate them to 
act inside their own sector in a way that the risk that pharmaceutical residues represent is 
reduced. This means that the pharmaceutical industry is aware about the need to design 
pharmaceuticals that are less harmful to the environment and also to develop manufacturing 
processes so that less waste is produced. When it is reasonable and possible from the 
healthcare point of view, pharmacies and prescribers can consider choices that are less risky 
to the environment regarding prescriptions. Information that is focused for consumers 
points out the necessity of safe and sound pharmaceutical disposal. To support safe disposal, 
take-back programs for pharmaceutical residues have been implemented for example in 
Canada, Sweden and in Finland. Information about the harmful effects of pharmaceuticals 
and possibility to return pharmaceutical residues without extra fee can prevent consumers to 
dispose these chemicals by flushing them or mixing them with other domestic wastes.  
Even if we prevent or, more realistically, reduce the unused pharmaceuticals ending up in 
our wastewater by controlling their disposal, those drugs that are consumed usually are 
excreted and so disposed with wastewater. Wastewater is a main entry for these pollutants to 
the environment. As a part of the prevention approach it is possible to separate highly 
concentrated wastewater produced for example by pharmaceutical industry, hospitals and 
nursing homes. Then we can treat this wastewater regarding pharmaceuticals before 
discharging it to the centralised drainage and wastewater treatment plant. Since urine 
contains most of the drugs that are excreted we can separate it and treat it before it is 
discharged to the treatment plant. To be able to treat more concentrated wastewaters, onsite 
facility is needed. Urine separation needs special toilets and new drainage structures. These 
might require high investments. On the other hand since urine contains also most of the 
nutrients ending up to wastewater, urine separation would benefit also nutrient removal. 
In addition to the preventative approach treatment possibilities have been studied. Results 
from conventional centralised wastewater treatment plants show that certain pharmaceuticals 
can be removed or at least it is possible to reduce the amount of some pharmaceuticals with 
treatment. Chemical structure and certain treatment parameters effect how effective the 
removal is. In this study sludge retention time (SRT) and nitrification process have been 
discussed. Also some advanced technologies like ozonation and membrane technology have 
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been acknowledged. According to studies it seems that long SRT and a good nutrient 
removal increases degradation chances of certain pharmaceuticals. Also ozonation and 
membranes have been discovered to have a potential to reduce or eliminate such 
compounds. However it has been noted that ozonation and membrane technology can be 
expensive way to treat wastewater.  
Despite the potential of centralised solutions, there is an inevitable fact that a considerable 
share of the population is not, and cannot, be connected to centralised systems. In these 
cases wastewater can be treated onsite in decentralised wastewater systems. Decentralised 
systems have various benefits when compared to centralised systems. These include, for 
example, reduced investments regarding drainage, possibility to recycle nutrients and water 
reuse, flexibility regarding population growth and in the case of operational failure, 
environmental problems are usually smaller when compared to centralised systems. Well 
maintained systems can reach high quality treatment regarding BOD and nutrients. However 
there was not information available about how decentralised systems can treat 
pharmaceuticals. 
To be able to evaluate the role that decentralised wastewater treatment systems can have 
regarding risk management and pharmaceutical residues in aquatic environment, laboratory 
experiments were implemented. Research was implemented with a bench scale recirculating 
biofilter (RBF). Regarding conventional centralised waste water treatment systems (WWTS), 
it seems that if the treatment process includes nitrification (conversion of ammonia to 
nitrate) the process can also remove certain pharmaceuticals. Therefore during the 
experiments both ammonia removal and pharmaceutical removal were observed by analysing 
concentrations in system influent and system effluent.  
Based on the results of laboratory experiments and statistical analysis it can be stated that 
RBF bench scale systems were able to remove both ammonia and four selected 
pharmaceuticals. Regarding the results it seems that small scale systems can also reduce 
pharmaceuticals from wastewater as centralised WWTSs. Also ammonia removal was highly 
effective. It seems that by using crushed glass as a filtermedia it is possible to remove almost 
all ammonia from wastewater. It also seems that geotextile as a filter media is not as effective 
as crushed glass. Analysed samples indicated that biofilter was also able to denitrify (convent 
nitrate to nitrogen gas). According to the laboratory analyses the average removal of 
gemfibrozil, naproxen and ibuprofen was more than 90 percent and diclofenac was removed 
by average little more than 70 percent. 
Based on these experiments it is clear that it cannot be assessed if the removal efficiency is 
similar regarding field systems. More research is needed to determine this. Experiments 
show some similarities with the previous results from centralised systems which stated that if 
the system removes nutrients, also pharmaceutical degradation is possible. This indicates that 
it might also be possible to remove pharmaceuticals from wastewater with field RBF and in 
addition removal could be possible with other decentralised systems that remove ammonia. 
When interpreting experiment results it should be noted that there are limitations. The 
pharmaceutical concentrations that were used during experiment were higher than the 
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measured concentrations in wastewater usually are. It might be that if there are low 
concentrations of pharmaceuticals in the influent, the removal effectiveness will differ. Also, 
because during the experiments, treated wastewater and not raw wastewater was used (even 
though the ammonia level was the same), it might be that when there is more organic 
material in the water, the removal effectiveness differs.  
At the moment there are no requirements for wastewater treatment regarding 
pharmaceutical residues but this might change in the future. Even though there can be 
requirements regarding pharmaceutical removal in the future, it should be noted that 
wastewater treatment currently, but also most probably in the future is focused on removing 
organic matter and nutrients and it would be extremely expensive to design and construct 
treatment systems that are targeted on certain micro pollutants. Therefore it is important to 
know the capacity of current treatment systems regarding pharmaceutical removal. 
Acknowledging the current capacity it is possible to target for example preventative 
measures more efficiently. This means that when we know what we can treat we can try to 
prevent those pollutants that we cannot treat, reaching our watercourses.  
If field studies show that decentralised systems can have a similar ability to remove 
pharmaceuticals in wastewater than centralised systems, it means for example that it is not 
necessary to prefer centralised wastewater systems regarding pharmaceutical removal. This is 
important for communities with low investment abilities, special needs regarding water reuse 
and system flexibility. It is also important to note that linkage between nutrient removal and 
pharmaceutical removal highlights the importance of maintenance of the treatment system. 
This means that removal of both pollutants requires stable operation of the treatment 
system. 
It seems that both in the European Union area and in North America research currently is 
focused on fate research, developing analytical methods and risk assessment measures as well 
as studying effects of different pharmaceuticals on the environment and human health. Also, 
development of different risk management measures is included. When research covers all 
the levels including risk assessment and risk management measures, the results benefit the 
whole sector. For example when we know that naproxen is effectively removed from 
wastewater using conventional treatment methods regarding both centralised and 
decentralised systems, it might not be then our main priority to study how this substance 
effect to aquatic organisms. When we learn more about the effects of different 
pharmaceuticals, their fate in the environment and possibilities to prevent or treat this 
pollution, we can select the most efficient risk management measures. This means that in the 
future we will have integrated solution for risk management including both preventative and 
treatment management approaches. 
5.2 Recommendations 
This research looked into the possibility to remove pharmaceuticals from wastewater using a 
nitrifying biofilter. This was done because there are indications that wastewater treatment 
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systems that are capable of ammonia removal can also reduce pharmaceuticals in the 
wastewater. Based on this research it cannot be stated if ammonia removal and 
pharmaceutical removal have a connection. The next step regarding laboratory experiments 
would be to study if removal of pharmaceuticals appears also when nitrification is inhibited 
in the biofilter. This way it might be possible to gain a deeper understanding about the 
pharmaceutical removal process. When we have a fuller understanding about the 
mechanisms and parameters that influence the reduction process it is possible to design 
more efficient treatment systems or develop the current systems so that we use them with 
maximum capacity regarding micro pollutants. 
To be able to evaluate further the role that decentralised systems can have as risk 
management measures regarding pharmaceuticals and the environment, it is necessary to 
implement field studies. These studies should include analysing pharmaceutical removal 
effectives of different decentralised applications. This is important since it might be that 
different technologies can have a different capability to remove pharmaceuticals. Also when 
we have more knowledge about which systems represent the best practice in this field, it is 
easier for both authorities and property owners to choose a treatment system that is needed 
depending of the location of the treatment plant and the sensitivity of the environment. 
Phosphorous removal is included for example in Sweden and in Finland to the treatment 
requirements for decentralised small scale systems. This is because phosphorus is one source 
for eutrophication in natural water systems. Therefore, in addition, it would be important to 
study the RBFs phosphorous removal efficiency since it seems that it has not been 
researched.  
From a policy development point of view in current situation, it would be important to 
clarify how to interpret risk assessment results. It is important to develop systematic 
procedures for risk assessment but as important it is to have a commonly agreed system how 
to include values like the precautionary principle to the environmental risk assessment. 
Policy developers should be provided training and information about the risk management 
procedures and weaknesses that they include. On the other hand harmonised and further 
developed methods for risk assessment (as they are developed in the EU for example) will 
help the interpretation in the future. 
Cost-effectives assessment regarding different risk management measures would offer a 
good base for policy directions in the future. In the future when we have more complete 
picture about the level of the risks that pharmaceutical residues in the environment 
represent, we can choose the most cost-effective measures to manage these risks. It is also 
important to study what is the capacity of our current infrastructure regarding micro 
pollutant removal. It might be that the most cost effective manner to reduce the risk is to 
first of all use our present treatment systems in a way that we reach the best level regarding 
treatment results in nutrient removal and second to select the most cost-effective ways to 
prevent pharmaceutical residues reaching wastewater. 
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Identification of the different structures like reducing pharmaceutical consumption (the use 
of a preventative approach), would offer better understanding how to focus risk 
management. Research should touch all the stakeholders and structures that can affect this 
issue. This means that stakeholders from the pharmaceutical industry to the single consumer 
as well as political and economical structures that support pharmaceutical used should be 
indentified and assessed. Identification and assessment should be implemented considering 
local and national conditions. 
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Experimental set-up for bench scale RBF 
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1 Water Balance and Loading Rates Determination 
The flow rate for the RBFs was determined by: 
AHLRQ *= = (0.20 m3/m2/d*(π*0.01252)= 0.000098174 m3/d -> 98.2 ml/d 
Where, 
 Q is the flow rate of septic tank effluent, ml/day,  
 HLR is selected hydraulic loading rate 0.20 m3/m2/d ∗ and  
 A is the filter column cross sectional area, m2. 
 
 Q Septic Tank =  98 ml/d 
According to USEPA (2002) recirculation tank is sized equal to 1.5 times the Q Septic Tank 
 Q Recirculation Tank = 1.5 * [Q Septic Tank] 
   = 1.5 * 98 ml/d 
  = 147 ml/d 
 
Specifications 
Effluent 
Septic
Tank 
Recirculating 
Tank 
Pump
Pump Air vents 
on the filter 
column 
cover 
Gravel
Filter Media
Effluent 
Tank 
A
v
3
v
1
v
2
v
4
HLR = 0.20 m3/m2/d 
Column Diameter = 25 mm 
Column Length = 23 cm 
Recycle Ratio = 4:1 
Dosing Frequency = 96 times/day  
 
∗ HLR follows USEPA recommendations 
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Volume per dose into the filter bed from the recirculation tank, mL/dose  
                            
V Dose = 
Q*(RecycleRatio+1)
DosingFrequency  
   =5.1 ml/dose ≈ 5 ml/dose 
 
Volume dose for Septic Tank effluent, m3/m2/day: v1 = Design HLR/Dosing Frequency 
Volume dose for Recirculating Tank effluent, m3/m2/day: v2 = (Recycle Ratio + 1)*v1
Volume dose for Recycled Filter effluent, m3/m2/day: v3 = (Recycle Ratio)*v1
Volume dose for RBF effluent, m3/m2/day: v4 = v1
 
         v1= Designed HLR 
             = 98 m3/m2/d /96 dose/day 
= 1,0 m3/m2/d 
= 1 ml/dose      
        v2 = (Recycle Ratio + 1) * v1
             = (4+1) * 1 ml/dose  
             = 5 ml/dose 
        v3 = Recycle ratio * v1
             = (4/1) * 1ml/dose 
                       = 4 ml/dose 
        v4 = v1 = 1 ml/dose 
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0.90Geotextile density = 
100 kg/m3
2 Steps to fill the biofilter media columns with geotextile 
A) Determine the volume filled by geotextile 
  Geotextile volume = Column total volume * (1-determined porosity) 
B) Determine the mass of geotextile 
  Mass of geotextile = geotextile * geotextile density 
C) Fill column with determined mass of geotextile evenly 
  Mass of the geotextile for the column filled 100 % with geotextile =  
  Column total volume * (1-determined porosity) * geotextile density 
   = 0,15  m * (π*0.01252  m2)* (1-0.90) * 100 kg/m3= 0.0007362 kg ≈ 736 g  
           
   Mass of the geotextile for column 3:1 = 25 % * 736 g = 184 g 
  Mass of the geotextile  for column 2:2 = 50 % * 736 g = 368 g 
  Mass of the geotextile for column 1:3 = 75 % * 736 g = 552 g 
 
 
 
Specifications  
Column Diameter = 2.5 cm 
Total Filter Length = 15 cm 
Geotextile porosity =  CG 3CG:1T 2CG:2T 1CG:3T T
CG:  Crushed glass
GT:  Textile
Geotextile
Crushed glass
Pea Gravel
25%
75%
50%
50%
75%
25%
100% 100%
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